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Drug eects can be unpredictable and vary widely among patients with environmental, ge-
netic, and clinical factors. Randomized control trials (RCTs) are not sucient to identify adverse
drug reactions (ADRs), and the electronic health record (EHR) along with medical claims have
become an important resource for pharmacovigilance. Among all the data collected in hospitals,
laboratory tests represent the most documented and reliable data type in the EHR. Laboratory
tests are at the core of the clinical decision process and are used for diagnosis, monitoring, screen-
ing, and research by physicians. ey can be linked to drug eects either directly, with therapeutic
drug monitoring (TDM), or indirectly using drug laboratory eects (DLEs) that aect surrogate
tests. Unfortunately, very few automated methods use laboratory tests to inform clinical deci-
sion making and predict drug eects, partly due to the complexity of these time series that are
irregularly sampled, highly dependent on other clinical covariates, and non-stationary.
Deep learning, the branch of machine learning that relies on high-capacity articial neural
networks, has known a renewed popularity this past decade and has transformed elds such as
computer vision and natural language processing. Deep learning holds the promise of beer
performances compared to established machine learning models, although with the necessity for
larger training datasets due to their higher degrees of freedom. ese models are more exible
with multi-modal inputs and can make sense of large amounts of features without extensive
engineering. Both qualities make deep learning models ideal candidate for complex, multi-modal,
noisy healthcare datasets.
With the development of novel deep learning methods such as generative adversarial net-
works (GANs), there is an unprecedented opportunity to learn how to augment existing clinical
dataset with realistic synthetic data and increase predictive performances. Moreover, GANs have
the potential to simulate eects of individual covariates such as drug exposures by leveraging the
properties of implicit generative models.
In this dissertation, I present a body of work that aims at paving the way for next generation
laboratory test-based clinical decision support systems powered by deep learning. To this end,
I organized my experiments around three building blocks: (1) the evaluation of various deep
learning architectures with laboratory test time series and their covariates with a forecasting
task; (2) the development of implicit generative models of laboratory test time series using the
Wasserstein GAN framework; (3) the inference properties of these models for the simulation
of drug eects in laboratory test time series, and their application for data augmentation. Each
component has its own evaluation: e forecasting task enabled me to explore the properties and
performances of dierent learning architectures; the Wasserstein GAN models are evaluated with
both intrinsic metrics and extrinsic tasks, and I always set baselines to avoid providing results in
a ”neural-network only” referential. Applied machine learning, and more so with deep learning,
is an empirical science. While the datasets used in this dissertation are not publicly available due
to patient privacy regulation, I described pre-processing steps, hyper-parameters selection and
training processes with reproducibility and transparency in mind.
In the specic context of these studies involving laboratory test time series and their clin-
ical covariates, I found that for supervised tasks, machine learning holds up well against deep
learning methods. Complex recurrent architectures like long short-term memory (LSTM) do not
perform well on these short time series, while convolutional neural networks (CNNs) and multi-
layer perceptrons (MLPs) provide the best performances, at the cost of extensive hyper-parameter
tuning. Generative adversarial networks, enabled by deep learning models, were able to generate
high-delity laboratory test time series, and the quality of the generated samples was increased
with conditional models using drug exposures as auxiliary information. Interestingly, forecast-
ing models trained on synthetic data exclusively still retain good performances, conrming the
potential of GANs in privacy-oriented applications. Finally, conditional GANs demonstrated an
ability to interpolate samples from drug exposure combinations not seen during training, open-
ing the way for laboratory test simulation with larger auxiliary information spaces. In specic
cases, augmenting real training sets with synthetic data improved performances in the forecast-
ing tasks, and could be extended to other applications where rare cases present a high prediction
error.
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Drug eects can be unpredictable.
Each novel therapeutics submied for approval to the Food and Drug Administration (FDA)
needs to be safe and eective for its intended use. However, FDA approval does not guarantee
safety and eectiveness for all patients. In fact, the response rates of patients to most major drugs
fall in the 50 to 75% range.[172] is is due to the variability in treatment response among pa-
tients, known as inter-patient variability, caused by factors such as the environment, genetics,
polypharmacy or comorbidities [178, 51, 199]. e consequences for drug safety are more con-
cerning: out of 222 novel therapeutics approved by the FDA between 2001 and 2010, 71 (32%)
were agged with post-market safety events, including 61 incremental boxed warnings for 43 of
these therapeutics [52]. Between 2008 and 2017, the FDA approved 321 novel drugs. Over the
same period of time, the FDA Adverse Event Reporting System (FAERS) recorded more than 10
million AE reports, among which 5.8 million were serious adverse drug reactions (SADRs), and
1.1 million were AEs related to death. AEs burden our health system causing 2 million hospital
stays each year and lengthening visits by 1.7 to 4.6 days[4]. e economic, social, and health
burden of these events make pharmacovigilance an essential and pressing public health concern.
What are the mechanisms in place?
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While clinical trials try to ascertain that a drug is safe and eective for its intended use before
its marketing, pharmacovigilance centers monitor AE reports and aim at ensuring that a drug’s
safety information is up to date. However, neither of these processes are error proof. On one
hand, clinical trials have focused on designing drugs for the average patient[182] even at a time
when there are increasing calls for precision medicine to enable the ”right drug at the right dose
to the right patient”[41]. On the other hand, spontaneous reporting systems are known to suer
from biases such as under-reporting which is especially troublesome for rare events and drug-
drug interactions (DDIs)[117]. erefore it is only by using post-marketing observational data
that we can uncover o-label uses, treatment paerns, patient specic variability in reponses,
and rare ADRs [73, 163, 164, 165, 166, 167].
e rapid adoption of electronic health record (EHR) systems stimulated by the HITECH
Act[5] over the past decade has made observational clinical data available to researchers more
than ever before. Among these observational data, laboratory tests stand out, as they represent
a direct measure of the patient’s metabolic chemistry. erefore laboratory tests have a crucial
role in clinical decision making for diagnosis, monitoring of treatment eects, screening of dis-
eases, and for research purposes to study the pathophysiology of particular disease processes
[198]. Laboratory tests can be used in two ways to monitor drug eects and inform treatment
decisions: either directly, with therapeutic drug monitoring (TDM) where the concentration of
the drug of interest is measured in the patient’s bloodstream to adjust individual dosage regimens
[91], or indirectly through other laboratory tests acting as surrogate substances. is laer phe-
nomenon is called drug laboratory eect (DLE). is eect of drugs impacting other chemicals
in the body is widely documented in the medical literature [189, 195, 170, 191, 206, 90]. It makes
laboratory tests a promising data type to study drug eects on patients.
Unfortunately, abnormal measures are oen made too late to avoid adverse drug reactions
[39] and very few automated methods use laboratory tests to inform clinical decision making
and predict drug eects. e reason is two-fold. Laboratory test time series are complex data
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objects: (1) they are ordered sequences of features; (2) they are irregularly sampled, meaning
that each patient has a dierent amount of measurements and the time intervals between mea-
surements varies; (3) laboratory measurements are contextual, and to get a full picture there is a
need for integrating categorical data such as diagnoses, procedures, drug exposures and demo-
graphic information; (4) laboratory test time series are usually non-stationary. Because of these
challenges, machine learning models that involve laboratory measurements usually include them
as features based on descriptive statistics of these time series (i.e., mean, standard deviation). A
few models have been centered on laboratory test time series but they aimed at predicting future
diagnoses [148, 150, 31]. To date, biomedical data science has only scratched the surface of the
potential laboratory tests have for clinical interventions. [62, 106]
When it comes to simulating drug eects, one of the main limitation is the the amount of
data available. While laboratory test time series are the most represented structured data type
in the EHR, some drug exposures are too rare to have satisfactory sample sizes. With the devel-
opment of novel deep learning methods such as generative adversarial networks (GANs), there
is an opportunity to learn how to augment existing clinical datasets with realistic synthetic data
and increase predictive performances. Moreover, GANs have the potential to simulate eects
of individual covariates such as drug exposures by leveraging the properties of implicit gener-
ative models. Instead of modeling every covariate and confounding variable, conditional GANs
can learn how to match auxiliary clinical information to conditionally learned distributions from
which they can be stochastically sampled. Although the amount of information these models
can retain naturally cannot exceed the information available in the input data, conditional mod-
els can disentangle information from other sample classes, and other combinations of auxiliary





In this dissertation, my goal is to study the use of conditional generative adversarial networks
(GANs) to model laboratory test time series and demonstrate how these models can be used for
the simulation of drug eects, with two main applications: (1) the inference of laboratory test
time series associated with drug exposure combinations unseen at training, and its direct con-
sequence, (2) the data augmentation of rare events to improve their predictability. ey provide
researchers with a new tool and open the path to synthetic data sharing, rare events prediction,
dierential privacy applications, and, down the road, could be integrated into next generation
clinical decision support systems. ese systems could be accessible to physicians who would in-
teractively modify some key clinical covariates, such as drug exposures, and implicitly leverage
the whole EHR to observe synthetic laboratory test trajectories that match their patient medical
history and demographic information beyond simply matching to existing trajectories. Moreover,
GANs have demonstrated in computer vision impressive performances for applications such as
style transfer, transfer learning, and data completion which are mentioned in the Background
and that could be translated into applications in healthcare that I will discuss in the future work
section.
As deep learning research provides new principled methods and mathematical guarantees
every day, it remains an empirical science where the vastness of the architectures and hyper-
parameters space needs to be explored for each new dataset. I structured this body of work to
follow a sensible and methodical progression through three specic aims. Aim 1 concerns the
exploration of what type of deep learning architectures are the most appropriate with laboratory
test times series and their covariates, using a forecasting task to compare them between each other
and to machine learning baselines. Aim 2 focuses on the development of GANs, non-conditional
and conditional, to model laboratory test time series and their evaluations, both intrinsic and
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extrinsic. Finally Aim 3 demonstrates the applications of these laboratory test GANs for data
augmentation re-using the forecasting models of the rst aims, and explores the simulation of
drug eects with conditional GANs.
Aim 1: Compare architectures and data representations for laboratory test forecasting
e rst task is to determine how to represent laboratory test time series with deep learning
architectures. To do so, I selected three routinely collected laboratory tests with dierent dy-
namic and physiological properties: blood glucose, urea nitrogen and hematocrit. Blood glucose
is used throughout this whole dissertation, and the two other laboratory tests are used as proof
of generalization in this aim only. I restricted these time series to a unique in-patient visit to par-
tially address stationarity, and the currency of the contextual data used. I evaluated dierent deep
learning architectures along with baseline machine learning methods, and the three dierent fea-
ture sets described below with a forecasting task. Supervised models are trained on n successive
measurements in order to predict the n + 1 value. It constitutes the general framework of this
aim.
Research question RQ1: How do deep learning models compare to classic machine
learning when it comes to forecasting regularly sampled laboratory test sequences?
is rst study consists of comparing classic machine learning and deep learning architectures
that can leverage the sequential nature of the LTTS and evaluate the advantages and disadvan-
tages of theses dierent methods. Only regular time series are selected for this study in order to
compare models without worrying about time intervals and covariates in the data representation.
Research question RQ2: How does the integration of time intervals in the forecasting
model aect performances?
Laboratory test time series representation for machine learning is a challenging problem,
with methods ranging from imputation [175, 183, 186, 16, 145, 187, 128, 151, 61, 119, 94, 20, 19]
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to integrating missingness paerns and sampling frequency into the representation itself[30].
In this study I extend the previously tested models to handle time intervals in the form of an
additional vector of features. is study evaluates the benets of using time information and
how deep models handle it compared to classic machine learning models.
Research questions RQ3: How can drug exposure auxiliary information improve
the forecasting task? How can this information can be integrated into deep learning
models? How do dierent drug exposure representations compare?
Finally, I added partial drug exposure information to the forecasting models and compared
how it improves the performances and what patients benet from such models. Since we want
GAN models that can make use of drug exposure information for beer modeling and simulation,
it is critical to test their integration and the impact they have on a simple forecasting task before
using them as conditional data in generative models.
e outcome of this rst aim is three-fold: it provides a baseline to understand the pros and cons of
deep neural networks to forecast LTTS, it constitutes an extrinsic evaluation of dierent architectures
and demonstrates how the rich contextual information collected with LTTS can be integrated in such
architecture, and it lays the foundation for the design of generative adversarial networks that can
model these complex objects. In addition, this forecasting task will be used in Aim 2 for the extrinsic
evaluation of the synthetic data generated, and in Aim 3 for the data augmentation task.
Aim 2: Develop generative adversarial networks (GANs) to model laboratory test time
series
In Aim 2, I developed and evaluated deep implicit generative models to learn distributions of lab-
oratory test time series. To this end, I used generative adversarial networks (GANs), an implicit
generative model framework that has demonstrated its eciency in learning complex distribu-
tions mainly in computer vision. [104, 201, 180, 60, 54, 97, 112, 12, 83, 194, 171, 203] I selected two
variants of the Wasserstein GAN (WGAN): the WGAN with gradient penalty (WGAN-GP) [69],
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and the WGAN with Lipschitz penalty (WGAN-LP) [138].
Research question RQ4: Can we learn complex distributions of laboratory test time
series (LTTS) using GANs?
To this day, only one previous study has applied GANs to medical time series and focused
on ICU time series with very large number of data points [55]; a problem very dierent from
modeling LTTS that are shorter and show uneven sampling. I developed a WGAN to generate
realistic synthetic LTTS and evaluated these models with two dierent methods: an intrinsic
evaluation using the Frechet distance that compares multi-variate gaussians appromixated on
the real and on the synthetic data; an extrinsic method proposed by Esteban et al. [55] called
Train on Synthetic, Test on Real (TSTR) using the previously developed forcasting models in Aim
1 to compare the real and synthetic datasets in a supervised learning task.
Research question RQ5: Can we train conditional GANs to generate LTTS realisti-
cally correlated with drug exposures?
For this study, I transposed the approach of the conditional GAN paper [125] to the WGAN
framework and used drug exposures that are signicantly dierentially associated with LTTS. I
evaluated how a conditional model compares to non-conditional models with the intrinsic and
extrinsic evaluations introduced in the previous section.
is second aim provides WGANs that can generate synthetic LTTS conditioned or not on drug
exposures. ese models, once evaluated, are ready for applications to real problems in biomedical
data science. While this dissertation focuses on drug exposure as auxiliary information for these
GANs, the conditioning could be extended to other covariates like diagnoses and procedures, and
include patient demographics, leveraging the rich literature in clinical data embedding to deal with
the sparsity of patient EHR representations. (see Background section)
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Aim 3: Use LTTS GANs for data augmentation and drug exposure simulation
Aim 3 put in action the GANs from the previous aim and illustrated two unique and comple-
mentary applications of these models. It builds on top of the forecasting models from Aim 1 that
are used for the data augmentation task, and expands on the possibilities oered by conditional
GANs with drug exposures.
Research question RQ6: Can we use conditional LTTS WGANs for drug exposure
simulation?
While Aim 2 evaluated the delity of the synthetic data generated by the conditional LTTS
WGANs, my goal here was to explore how we can simulate drug exposures unseen at training
with GANs. is study relies on the linear interpolation properties in the latent space of the
generator and its inference power. Indeed, since the generator takes in input a random vector
concatenated with a drug exposure vector, it is possible to generate laboratory test time series
with drug exposure combinations of our choice.
Research question RQ7: How can LTTS WGANs augment real datasets to improve
performances in supervised learning?
In this study, I augmented the training datasets of Aim 1 forecasting models rst with single
drug exposure time series, and then by targeting laboratory test time series associated with rare
drug combinations that yielded high error with the forecasting models of Aim 1.
e overarching goal ofAim 3 is to demonstrate the ecacy of implicit generative models trained
on laboratory test time series for two unique applications: data augmentation and conditional sim-
ulations. ese two examples open the door to more applications for both biomedical informatics
research and the development of next generation clinical decision support systems.
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1.1.2 Signicance and Contribution
is dissertation tackles signicant issues: 1/ the lack of tools to simulate drug exposures on lab-
oratory tests; 2/ insucient prior art in comparing machine learning and deep learning models
for supervised tasks involving laboratory tests; 3/ the integration of categorical covariates and
time series data in supervised and self-supervised tasks in healthcare; 4/ the development and ap-
plications of generative adversarial networks (GANs) on medical data that remains a very young
eld of research.
In the rst aim, I am using a simple forecasting task to compare machine learning and deep
learning supervised models. ere is lile prior art regarding the compared performances of these
models on laboratory test time series. Deep learning has demonstrated its superiority in domains
such as computer vision and natural language processing, but it unclear what its benets are in
healthcare and what are its trade-os in terms of computational cost and performances compared
to simpler models. Moreover, deep learning models are, in theory, innitely exible with their
high degrees of freedom, and their hyper-parameters tuning can be extremely time consuming.
Conversely, EHR data are multi-modal and complex, and it is important to evaluate the benets of
integrating laboratory test time series with other clinical data such as drug exposures. Very few
studies have integrated other clinical data to laboratory tests, and there is a debate regarding the
advantages of clock time versus sequential time when dealing with their temporal nature. With
this aim I intend to provide an in-depth evaluation of these dierent congurations of models
and features to advance the knowledge in laboratory test modeling.
In the second aim, I built deep generative models for laboratory tests and evaluated them
with two dierent methods. Developing evaluation metrics for generative models remains an
active eld of research. ese types of metrics have been thoroughly studied in the past couple
years in computer science, usually for computer vision applications, but there are no evaluation
metrics available when it comes to EHR data science and deep generative modeling of these
data. I will compare the Frechet distance, an intrinsic metric between real and synthetic data,
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and TSTR, an approach that compares the performances of a supervised learning model when
it is trained on synthetic data and tested on real data. e second tier of this aim introduces a
conditional Wasserstein GAN architecture for laboratory test time series with drug exposures as
the auxiliary information. is is a novel approach that opens the door for more comprehensive
conditional GANs that would use a variety of auxiliary data such as diagnoses, procedures, and
demographics and build on the rich literature on clinical data representation with deep learning.
ese generative models constitute the main contribution of this dissertation.
Finally, in my third aim, I illustrated the possibilities oered by GANs in healthcare with
two applications unique to generative models: data simulation and data augmentation. Data
simulation relies on the inference properties of GANs latent space. By exploring drug eect
simulations with conditional GANs, I provide a proof of concept for disentangling conditional
eects and simulate classes of samples never seen during training. Data augmentation is the
most straightforward application resulting from the simulation properties of LTTS GANs. It
could have a major impacts on biomedical research. We are oen confronted to situations where
machine learning models struggle to correctly learn manifolds for sample categories that have a
lower sample size. However, these samples are usually the most critical to learn (e.g., rare adverse
events, hard to predict drug responses). is aim represents a proof of concept for more complex
models that could handle patient trajectory inference to simulate laboratory test time series in
EHR systems for clinical decision support.
erefore, this dissertation will make available novel tools for both researchers and, down the
line, physicians. While the in-depth evaluation of deep learning models, both supervised, and self-
supervised with the GANs, will contribute to biomedical informatics research, the long term goal
is to see these novel approaches put into production in EHR system. I believe that GANs provide
a promising and exible framework for a variety of applications beyond data augmentation and
data simulation that could benet to well-known issues in biomedical informatics such as privacy-
preserving data sharing, transfer learning for phenotyping between institutions, and propensity
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is dissertation has general and aim-specic limitations. Although all my studies have been con-
ducted using the OMOP Common Data Model (CDM) and could in theory be adapted to any EHR
dataset following the same structure, the present dissertation has been conducted exclusively
at Columbia University Irving Medical Center/New York Presbyterian (CUIM/NYP). erefore
the present results could be implicitly biased by medical practices, billing practices, and Export
Transform and Load (ETL) practices that produced the research dataset I had access to. Future
works include replications in other large tertiary medical centers. Another general limitation
is that deep learning models are computationally intensive to train, and their hyper-parameters
space is extremely large. erefore, I could not replicate all my experiments for all the labora-
tory tests available and instead focused on three measurements that have dierent temporal and
physiological properties.
I decided to adopt a visit-centered approach and consider time series at the in-patient visit
scale. One could adopt a patient-centered approach at the cost of a high risk of non-stationarity.
Regarding the models compared, I focused on the most popular and representative models for
both machine learning and deep learning. As the state of the art evolves every day, I decided to
focus on the main architectures and leave more complex models such as aention mechanisms
with recurrent neural networks for future work. I also focused in this dissertation on drug eects.
Other studies explored the embedding of a variety of clinical data types like diagnosis codes and
demographic information that could be integrated into the GANs presented in this body of work.
I am aware that there are other types of generative adversarial networks (GANs) architectures
(e.g., ”Vanilla” GAN, maximum mean discrepancy (MMD) GAN, f-GAN…) but decided to focus
on the Wasserstein GAN for its stability and the successful replications of its results in the liter-
ature [69, 138]. e goal was to illustrate the potential of these models for biomedical sciences
rather than provide an exhaustive benchmark of the ever changing state of the art in computer
science. e family of generative models is not limited to GANs, and other models such as Vari-
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ational Autoencoders (VAEs) have also demonstrated interesting performances in other elds of
application.
Finally, as mentioned earlier, there is a wide range of promising applications for implicit gen-
erative models beyond data augmentation and data simulation and their are discussed more at
length in the last chapter of this dissertation.
1.2 Drug eects: from discovery to EHR surveillance
e U.S. Food and Drug Administration (FDA) has a precise denition of what a drug is [2]:
• A substance recognized by an ocial pharmacopoeia or formulary
• A substance intended for use in the diagnosis, cure, mitigation, treatment, or prevention of
a disease
• A substance (other than food) intended to aect the structure or any function of the body
• A substance intended for use in a component of a medicine, but not a device or a component,
part, or accessory of a device
In this section, I will give a background on drug eects, starting from the drug discovery
process with a focus on the populations exposed during the clinical trial phases, to the post-
marketing surveillance and the variables that can serve as proxies for drug eect detection in the
Electronic Health Records (EHR). I will discuss the link between laboratory tests and drug eects
and describe past studies involving laboratory tests time series (LTTS) in biomedical data science,
along with opportunities for using them in pharmacovigilance and clinical decision making.
Drug approval and pharmacovigilance
Drug discovery is a complex and arduous process that can take 12 to 15 years, from the basic
research leading to target identication and selection to the nal ling, and costs more than $1
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billion along the way[84], although exact estimation of drug development costs is hard to get and
experts oen disagree. [141, 47]
e drug development stages have various lengths, modalities, costs, and numbers of patient
exposed (Figure 1.1). Prior to any human testing, the pre-clinical stage or phase 0 involves animal
models to evaluate drug toxicity prior to any clinical trial. [158]. e FDA and the drug sponsor
interact throughout the drug development process. Before Phase I, the sponsor submits an In-
vestigational New Drug (IND) application to the FDA once the pre-clinical trials are done. ey
discuss aer Phase 2 to determine how large-scale studies in Phase 3 will be conducted. Aer
Phase 3, the FDA and the drug sponsor have a review meeting prior to the submission of a New
Drug Application (FDA) from the drug sponsor. From there, the FDA has 60 days to review the
NDA. e last stages involve the drug labeling and facility inspection by the FDA, concluded by
either the drug approval or a response leer.
Figure 1.1: Characteristics of Clinical Trial Phases [188]
Of course, because a drug is approved for a certain indication does not mean it will be ecient
or safe for everyone. Most major drugs are eective in only 25 to 75% of the patients.[172] One of
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clinical pharmacology’s central goals is the quantitative prediction of drug eects. is problem
has two faces: pharmacokinetics (PK) and pharmacodynamics (PD). Pharmacokinetics relates to
what the body does to the drug, through the processes of absorption, bioavailability, distribution,
metabolism, and excretion. Pharmacodynamics relates to what the drug does to the body, with
concepts such as receptor binding, postreceptor eects, and chemical interactions. e PK/PD
system is intimately related to drug eects; unusual pharmacodynamic eects being related to
unusual responses of drug receptors to a normal concentration, while unusual pharmacokinetic
eects represent normal receptors being exposed to unusual concentrations. [178]
e unpredictability of drug eects arises from multiple factors contributing to PK and PD,
and therefore to the variability in drug responses. ese factors can be environmental, genetic, or
disease determinants; genetic factors being the most studied with pharmacogenetics and the ex-
tensive exploration of a superfamily of microsomal drug-metabolizing enzymes, the cytochrome
P-450 enzymes.[51, 199] Turner et al.[185] performed an extensive review of the inter-individual
drug variability, advocating for the relevance of domains such as systems pharmacology or com-
putational pharmacology; domains that can integrate various data modalities with the potential





• Human body levels:
– Genome: On-target, O-target, drug metabolizing enzymes (DME) function, xenobi-
otic transporters (XTs), Transcription factors
– Epigenome: DNA methylation, microRNA
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– Proteome: Protein synthesis regulation, Serum protein levels
– Metabolome: Purine metabolism
– Tissue/organ: Anatomical, physiological
– Pathophysiological: concomitant diseases, iatrogenic illnesses
• Environmental:
– Drugs, smoking, and concomitant food intake
– UV exposure
Unfortunately, clinical trials still present regulatory and structural biases. For example, the
FDA still considers women and the elderly to be special subgroups; leaving important gaps in
the understanding of drug eects in these population, in spite of age and sex being important
factors in PK/PD dierences.[181] Drug development has been focusing on designing drugs for
the average patient, ignoring some aspects of diversity, while paradoxically precision medicine
aims at tailoring treatments based on individual variability. [40]
Moreover, there is a multitude of covariates that can only be observed once the drug has been
put on the market causing eects such as drug-drug interactions, a change in ecacy or toxicity
of one drug by prior or concomitant administration of a second drug [159], which increase in
occurrence is tied to an increase in polypharmacy [71]. Such eects would be simply impossible
to test for in a clinical trial seing, due to the mere combinatorial complexity of the task. As a
consequence, the safety of a drug is oen updated aer the drug has been put on the market. As
an illustration, Downing et al.[52] conducted a cohort study of all novel therapeutics approved
by the FDA between January 1, 2001 and December 31, 2010. Out of the 222 novel therapeutics
(183 pharmaceuticals and 39 biologics) approved by the FDA during that period, there were 123
new postmarket safety events (3 withdrawals, 61 boxed warnings, and 59 safety communications)
during a median follow-up period of 11.7 years for 71 (32.0%) of the novel therapeutics.
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ese staggering amounts of postmarket safety events highlight the important role of post-
marketing surveillance, a branch of pharmacovigilance that starts at Phase IV of drug develop-
ment and continues throughout the whole life cycle of a drug. Pharmacovigilance, or drug safety,
includes the monitoring and evaluation of adverse drug reactions (ADRs). A wide range of in-
stitutions and centers around the world work toward drug safety monitoring, from the ality
Assurance and Safety team within the World Health Organization (WHO), to the Uppsala Mon-
itoring Centre in Sweden that manages the international database of ADR reports received by
national pharmacovigilance centers [135], including hospitals, universities, health professionals
and patients themselves.[88]
In the United States, the FDA Adverse Event Reporting System (FAERS) is the database that
stores adverse event reports, medication error reports and product quality complaints resulting in
adverse events that were submied to the FDA. From its earliest records in 1968 to March 31, 2018,
the FAERS database counts more than 15 million adverse events reports, 8.7 million of which were
for serious drug adverse event reactions (SADRs), and 1.5 million of which were death reports. In
2017 only, 906,773 serious drug adverse events were reported and 164,154 adverse events related
deaths.
But adverse event reporting databases are not the only tools drug safety can count on. Elec-
tronic medical record (EHR) and claims data represent an opportunity to monitor drug safety
in real time using routinely collected data. is secondary use of the EHR also faces impor-
tant challenges, including the lack of gold standard for known ADRs,[42] the technical diculty
from the natural language processing standpoint of extracting ADRs embedded in the free text
of clinical notes [107] or vocabulary issues that impede ecient Named entity recognition of the
concepts[131]. Regardless, a large number of studies have been conducted using EHR and claims
data to detect, predict and investigate drug side eects [18, 165, 184, 156, 99, 209, 154, 155, 153, 152].
Another issue that has been plaguing observational studies is the lack of reproducibility, with
studies contradicting themselves when trying to answer the exact same question[118, 86], or even
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producing false ndings [85]. To address these challenges in observational data, techniques such
as p-value calibration [163, 164], condence interval calibration [166] and systematic approaches
for high-throughput evidence making [167] have been developed in the recent years to greatly
increase the robustness and rigor of these analyses.
Laboratory tests and drug eects
Among all the data available in the EHR, laboratory tests constitute the bulk of it, representing up
to 70% of all the stored data [136]. Laboratory data can be either quantitative results, or laboratory
tests, and qualitative information under the form of pathology reports, mostly in free text form.
Laboratory tests also benet from a high accuracy in their transmission from laboratory to EHR
system, with Perroa et al.[137] nding an overall accuracy of 99.3% and completeness of 69.6%.
Laboratory tests also represent crucial information for evidence-based clinical care and med-
ical decision analysis.[116] ey are essential to the diagnostic decision making process and pa-
tient management,[198] and are generally ordered for four major legitimate reasons:
• Diagnosis (to rule in or rule out a diagnosis).
• Monitoring (eg, the eect of drug therapy).
• Screening (eg, for congenital hypothyroidism via neonatal thyroxine testing).
• Research (to investigate the pathophysiology of a particular disease process).
Studies have investigated the way laboratory tests impact medical practice, evaluating for
example how oen frequently ordered tests lead to clinical decisions when they return abnormal.
Some tests are more impactful than others, like abnormal blood urea nitrogen (BUN), creatinine,
or potassium levels, while other abnormal tests trigger less actions even when abnormal.[200]
e monitoring usage of laboratory tests is of particular interest to study drug eects using
EHR data. is monitoring can be perform directly, by measuring the drug concentration in the
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patient serum, or indirectly, by measuring surrogate laboratory tests that can inform on the drug
eect.
e former practice is called therapeutic drug monitoring (TDM). It is ”the clinical practice
of measuring specic drugs at designated intervals to maintain a constant concentration in a
patient’s bloodstream, thereby optimizing individual dosage regimens.”[91] and is a standard for
therapies such as antiepileptic drugs, digoxin, psychiatrics, and immunosuppressant drugs.
e laer practice, or how drug would aect laboratory tests that could become surrogate
variables to study their eect, is called drug laboratory eect (DLE). ese eects are classied
into three categories: physiological, pharmacological or toxicological.[170] ese biological ef-
fects, or DLEs, can be used to monitor treatment by potentially hazardous drugs, for example
cardiac glycosides like digoxin mentioned above, but are oen considered to be interferences or
perturbations adding bias to the laboratory test values [189, 195, 191, 206]. ere are more than
40,000 drug eects on laboratory tests reported in the literature [207], but they usually cause
misinterpretation of laboratory data and lead to unnecessary further tests, missed diagnoses, and
additional costs, instead of actually helping physicians, calling for computerized support.[90] For
ADR monitoring, the challenge is to devise a monitoring scheme that would detect an ADR be-
tween the earliest time a deviation from the normal is observable, but before the patient is actually
at risk [39].
DLEs ave the opportunity to be used more eciently in the EHR, for example improving
laboratory monitoring of patients receiving high-risk drug therapy likely to induce hepatotoxi-
city, with the potential to decrease complications and costs of therapy[144] or monitoring bri-
nolytic therapy when brinogen levels are low and there is a need for using surrogate laboratory
tests.[168]
e feasibility of identifying DLEs in the EHR has been proven, with a number of studies in-
volving lagged linear models and time-delayed mutual information (TDMI)[9]. Although the EHR
reects the healthcare recording process instead of a direct reection of the patient health status,
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Hripcsak et al.[78] showed that the appropriate time representation can enable the use of clinical
databases. In particular, they found that sequence time produces stationarity in the time series of
interest.[79] Using these methods, Hripcsak, Albers and colleagues [9, 10, 77] demonstrated that
it is possible to identify meaningful and high-delity therapeutic and physiologic processes in
the EHR by using time-series methods. More recently, Levine et al. [108, 109] showed that lagged
regression was an ecient method to detect physiologic drug eects.
In spite of the incredible potential of using laboratory test time series, very few studies have
tried to leverage laboratory tests. MetaLAB by Lee et al.[106] proposed to ag adverse drug
reactions (ADRs) using abnormal laboratory results as ADRs signals and compute odds ratios to
compare study and comparison groups. Only one study [62] tried to eectively mine drug eects
using laboratory tests results by building a model that uses drug information and EHR data to
infer DLEs.
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1.3 Biomedical Data Science
Secondary use of the Electronic Health Records
Electronic health record’s (EHR) widespread adoption has fast-tracked the digitization of health-
care data and enabled the secondary use of EHR data for research purposes. In 2016, according to
the Centers for Medicare and Medicaid Services (CMS) and the Oce of the National Coordinator
(ONC) for Health Information Technology (HIT), over 95% of hospitals eligible for the Medicare
and Medicaid EHR Incentive Program achieved meaningful use of certied health IT (Figure 1.2).
Figure 1.2: Percent of All Eligible and Critical Access Hospitals that have Demonstrated Mean-
ingful Uses of certied Health IT — 2016, CMS
When parsed by hospital bed size, the majority of hospitals within each hospital type are
meaningfully using certied health IT. More than 90 percent of large, medium, small rural, and
critical access hospitals were meaningfully using certied health IT, and more than 4 in 5 small
urban hospitals were meaningfully using certied technology. Children’s hospitals have the low-
est rate of meaningful use achievement, with over 3 in 4 children’s hospitals having achieved
meaningful use. Nearly 90 percent of all hospitals have demonstrated stage 2 of the program
(Figure 1.3).
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Figure 1.3: Hospital Progress to Meaningful Use by Size, Type, and Urban/Rural Location — 2016,
CMS
e wealth of data available in the EHR is heterogeneous in their nature and modality, mak-
ing their use challenging (Figure 1.4). But it has been catalyzed by three decades of Biomedical
Informatics research, developing the knowledge representations, standards, collaborations and
methods to facilitate and enable the information extraction process from the EHR. ey include:
• Knowledge representations: the MED [38], UMLS [25], SNOMED [50]
• Terminologies and Standards (ICD10 [174], CPT-4 [21], LOINC [120], RxNORM [113])
• Semantic interoperability: [176], HL7 [48] and FHIR
• Clinical Data Models (CDMs): Clinical Data Interchange Standards Consortium (CDISC)
Study Data Tabulation Model (SDTM)[3], the mini-SENTINEL CDM from the Food and
Drug Administration (FDA) [43], the PCORnet CDM from the Patient-Centered Outcomes
Research Institute (PCORI) [7] and the Observational Health Data Sciences and Informatics
(OHDSI) CDM [6]
• Initiatives such as Informatics for Integrating Biology & the Bedside (i2b2[130]) and OHDSI
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Figure 1.4: Overview of data types of modalities in the EHR
[81] seek to produce open-source frameworks that allow dierent teams of researchers to
run the same analyses on separate private databases, and combine the results with con-
dence in order to eectively achieve the benets of data aggregation on closed data
• Natural Language Processing (NLP): MedLEE [59], MetaMap [15], cTAKES [162]
At the same time, computer science, and more specically machine learning, has reached
critical mass, with enough computational power and novel methods to turn any dataset into an
actionable source of information. To quote Patricia Brennan, Director of the National Library of
Medicine (NLM) and colleagues in a JAMIA editorial in 2017: ”Biomedical informatics has thus
evolved and overlaps signicantly with biomedical data science, the subeld of data science that
is concerned with discoveries using primarily clinical and other health-relevant data.” [28]
However as mentioned earlier, EHR data are noisy and messy, and a lot of eorts have been
dedicated to characterizing the challenges of using EHR data for research. According to Hripcsak
et al.[76], these challenges are: Completeness, Accuracy, Complexity and Bias (Table 1.1).
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Challenge Description
Completeness
• Missing by mistake, expected to be recorded but lacking
• Missing because the patient went to another institution, health information
exchange insuciently pervasive, data fragmentation
• Data only recorded during healthcare episodes, corresponding usually to ill-
nesses
• Missing data due to implicitness, pertinent negative ndings
Accuracy
• Observing the patient
• Conceptualizing the results
• Recording them in the records
• Recording is inuenced by billing requirements and avoidance of liability
(systematic error)
• Mismatch between the nominal denition of a concept and the intent of the
author
Complexity
• Complexity of the knowledge representations, and their maintenance
• Complexity on the data types, heterogeneous: structured data, semi-
structured text, free-text narrative notes requiring a wide range of methods
such as natural language processing to extract information from them
• Temporal aributes are highly complex, time scales from seconds to years
with dierent levels of uncertainty
Bias
• e above challenges including systematic errors can result in signicant bias
when health record data are used naively for clinical research
• Healthcare is a complex set of processes with many feedback loops
Table 1.1: Challenges of the EHR [76]
Various studies have investigated EHR data quality assessment, where quality is seen as a
”tness for use” concept. In Weiskopf et al.[196], the authors identied ve dimensions of data
quality:
• Completeness: Is a truth about a patient present in the EHR?
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• Correctness: Is an element that is present in the EHR true?
• Concordance: Is there agreement between elements in the EHR, or between the EHR and
another data source?
• Plausibility: Does an element in the EHR make sense in light of other knowledge about
what that element is measuring?
• Currency: Is an element in the EHR a relevant representation of the patient state at a given
point in time?
From there, we can formulate a number of predictive tasks that can be addressed with EHR
data. Predictive problems include disease onset and progression prediction, treatment choice
prediction, treatment response prediction or treatment safety, predicting adverse drug reactions
(ADRs). All these prediction tasks can be addressed with various supervised machine learn-
ing methods, and are patient-level prediction. is is dierent from causal risk factor that are
population-level eect estimation, in the realm of causal inference that I will not discuss here.
In the past few years, machine learning has had an increased focus on neural networks lay-
ing the foundations for deep learning. While machine learning methods usually require feature
engineering, deep learning solves this central problem in representation learning by introducing
representations that are expressed in terms of other, simpler representations (Figure 1.5.[64]
In Figure 1.6, we can see how a deep learning model piles several layers of abstraction of
the image features, from the simplest at the pixel level to more complex concepts by identifying
object parts.
erefore, it seems that deep learning would provide a powerful set of methods for biomedical
data science challenges, being ecient at:
• Discovering intricate structures in high-dimensional data, uncovering complex non-linear
relationships between features [103]
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Figure 1.5: How dierent parts of articial intelligence relate to each other. Greyed boxed are
processes that learn directly from the data [64]
• Dealing with multi-modal data [177]
• Unsupervised learning to learn disentangled representations of the data [22]
Indeed, an increasing number of studies with EHR data are using deep learning, focusing on
ve areas[202] (Figure 1.7):
1. Disease detection/classication refers to the tasks of detecting whether specic diseases
can be conrmed in the EHR data.
2. Sequential prediction of clinical events refers to predicting future clinical events based
on past longitudinal event sequences.
3. Concept embedding is algorithmically deriving feature representation of clinical concepts
or phenotypes from EHR data.
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Figure 1.6: An example of a deep learning model for computer vision [64]
4. Data augmentation is creating realistic data elements or patient records based on real
EHR data.
5. EHR data privacy refers to the techniques that protect patient EHR privacy and conden-
tiality, eg., de-identication.
us, an important question remain to be answered: what are the requirements to pre-process
EHR data to represent patients in deep learning?
Patient representation for machine learning
e concept of missingness is probably one of the most important, given the uncertainty burden
it puts on the data. It aects both the data quality and the data representation. It has been theo-
rized by Rubin[160], who put missingness into three distinct categories: missing-completely-at-
random (MCAR), missing-at-random (MAR), and missing-not-at-random (MNAR). MCAR means
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Figure 1.7: Transform longitudinal EHR data into input vectors (top le), which could support
dierent analytics tasks described in the survey (top right). with deep learning architectures
(boom)[202] – gure reproduced under a license agreement with Oxford University Press.
that the probability that a data point is missing is independent from the value of the data or the
value of any other variable. MAR means that once having controlled for all other known variables
(ie., conditional on these variables), the probability that a data point is missing does not depend
on the value of that data point. Finally, MNAR means that the probability that a data point is
missing depends completely on the value of that data point or on the value of other unmeasured
variables.
In EHR data, missingness can be interpreted as dierent phenomenons. If we consider mul-
tiple laboratory test time series (LTTS) in a univariate model and align the sampling times of
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each laboratory test, then missingness will be the values of the test not performed at a given time
stamp. Missingness can also arise from a re-sampling process that transforms a time series into
a sequence of values, and values of the sequence that were not measured for the new time stamp
are missing. Another type of missingness arises when one aggregates features over a specic pe-
riod of time (e.g., medications, procedures, diagnoses, averaged laboratory test values) and that
one or several features are missing for a given patient.
One way to address this missingness is imputation. ere is a large number of methods for im-
putation. Some are simple, performing simple mean/mode imputation, interpolations or splines.
Others are more comprehensive methods that learn correlations across samples and features, like
missForest[175], kNNimpute [183], Multiple Imputation by Chained Equations (MICE) [186, 16,
145, 187], spectral analysis [128], kernel methods [151], EM algorithm [61], matrix completion
[119] and matrix factorization[94]. More recently, deep neural network methods involving auto-
encoders have even been developed to impute missing data in aggregated matrices.[20, 19]
However, one could argue that in the case of informative missingness, imputing missing val-
ues could in fact destroy information contained in the missingness paern.[197] erefore some
approaches using laboratory test time series (LTTS) for prediction tasks have been using vectors
of data with missing values along with mask binary vectors indicating which values are missing,
and let the deep neural network handle the feature learning.[30]
erefore, another approach to representing EHR data for deep learning is to let the model
carry the burden of the representation by feeding it multi-modal data with no imputation, like
Che et al. suggest above. ere has been an eort to apply deep learning on EHR data to gener-
ate compressed representations that improve the performances of learning tasks by taking care
of messiness and missingness altogether in their non-linear transformation process.[169] One of
the studies that had signicant coverage was the Deep Patient model [124]. Mioo et al. gener-
ated bag-of-words counts of clinical codes and concepts extracted from clinical notes with simple
concept extraction methods, and then produced so clusters with Latent Dirichlet Allocation
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to compress these large vectors into a more tractable dimensional space. ey then fed these
compressed vectors into stacked denoising autoencoders to learn an even more compressed rep-
resentation, leveraging the network’s non-linearity.
Other approaches involved:
• Semantic Embeddings [123, 100]:
– summing word-level skip-gram embedded vectors of clinical codes to create a full-
record representation[34]
– using a multi-level embedding model that represents a single patient visit as a skip-
gram-type embedding of precomputed word-level code embeddings similar to skip-
gram vectors but constrained to have non-negative values for interpretability [33]
– generating word-level semantic embeddings for diagnosis and intervention codes [139]
– using word-level embedding [133]
– using full-record semantic embeddings [17]
• Encoding temporality
– using time-stamped events as inputs to a particular type of Recurrent Neural Network
(RNN) to predict future disease diagnosis [32] .
– using temporal matrix representations using codes in rows and years in columns as
inputs to a deep Boltzmann machine [121]
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1.4 Generative Adversarial Networks
Principles of GANs and signicant architectures
Generative models
Statistical classication is divided into two categories: discriminative models and generative mod-
els. Let X be an observable variable and Y the label. In a discriminative model, we learn the
posterior probability p(Y |X = x) given an observation x, mapping directly an instance to its
label. In a generative model, we learn a model of the joint probability distribution p(X, Y ) and
then make predictions using Bayes rule to calculate p(Y |X = x). Both model families can benet
from dierent situations: generative classiers can approach their asymptotic error faster as the
number of samples increases, and discriminative classiers can approach their lower asymptotic
error and outperforming generative models [132].
Figure 1.8: A taxonomy of deep generative models [63]
Generative models have another advantage: they are theoretically able to sample synthetic
data points because they learn a probabilistic model over the data. ere are two types of prob-
abilistic models: prescribed models and implicit models.[46] Prescribed statistical models are a
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parametric specication of the distribution of a random vector X , leading to a log-likelihood
function:
L(θ) = ln f(x; θ)
Where f(.) is a class of distributions, x a set of observable data and θ a vector of parameters.
Implicit generative models are dened as ”a stochastic mechanism whereby the data are gen-
erated” [46]. ey take as an input a latent variable z and map it using a deterministic function
Gθ dened on Rm → Rd using parameters θ.
A general expression for an implicit generative model, with a valid density on the output
space that forms an eective likelihood function, is given by Mohamed et al.[127]:










Now if the functionGθ is specied by a deep neural network, it becomes non-linear and d > m.
e integral becomes intractable, therefore calling for likelihood-free alternative.[127]
Generative adversarial networks
Generative adversarial networks (GANs) are an implicit density (Figure 1.8) framework proposed
by Goodfellow et al. in 2014 [65], where a generator network G maps random latent variables
to synthetic samples in order to fool a discriminator network D that classies real and synthetic





V (D,G) = Ex∼pdata(x)[logD(x)] + Ez∼pz(z)[log(1−D(G(z)))]
e training process of GANs diers from the training of other neural networks architecture
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(Figure 1.9) in the sense that we are optimizing two neural networks one aer the other at each
epoch, in order to approach a Nash equilibrium. e Nash equilibrium is dened as a stable state
where neither the generator nor the discriminator can gain by a unilateral change of their weights
if the other remains unchanged. ere is no guarantees for reaching the unique Nash equilibrium
of the zero-sum game that corresponds to pdata = pmodel where the Jensen-Shannon divergence
is minimized. Indeed, it is possible to show that the minmax game above is an approximate
minimization of the symmetric Jensen-Shannon divergence, where P is the target distribution
and Q the learned distribution:
DJS(P ||Q) = 1
2




with DKL the Kullback-Leibler divergence.
Figure 1.9: Training algorithm of the ”Vanilla” GAN [65]
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Soon enough, GANs went from multi-layer peceptron (MLP) networks to nding the right
convolutional neural network (CNN) architecture and deal with images [143], bringing some
modications to classic CNNs to produce good quality synthetic images:
1. Strided convolutions in place of pooling layers [173]
2. Fractional-strided convolutions instead of image upsampling
3. e only fully connected layers are the input of the generator and the output of the dis-
criminator
4. Batch normalization [87] to prevent mode collapse, except at the output of the generator
and input of the discriminator
However, the DCGAN still used the same Jensen-Shannon divergence minimization scheme
introduced by Goodfellow et al.[65] in the seminal paper, causing training to be arduous with
several papers trying to address the issues by suggesting training techniques for GANs[161] or
aempts at principled approaches [13]. Among these techniques: feature matching, minibatch
discrimination, historical averaging, one-sided label smoothing, virtual batch normalization, are
as many tricks trying to make up for the massively unstable GAN training in this formulation.
erefore there has been some exploration to determine what is the most suitable distribution
measure scheme to train GANs, as we know implicit models can be trained using two dierent
approaches: density dierence or density ratio (Figure 1.10). e f -GAN [134] demonstrates that
the classic or ”Vanilla” formulation of the GAN framework with a Jensen-Shannon divergence is
a special case of a broader and more general variational divergence estimation approach. In this
study, Nowozin and colleagues show that any f -divergence can be used for training GANs.
Given two distributions P and Q that possess, respectively, an absolutely continuous density
function p and q with respect to a base measure dx dened on the domain X , an f -divergence
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Figure 1.10: Summary of approaches for learning in implicit models [127]
is dened by:









where the generator function f : R+ → R is a convex, lower-semicontinuous function
satisfying f(1) = 0. f -divergences include Kullback-Leibler, Reverse KL, Pearson χ2, Squared
Hellinger and Jensen-Shannon.
Yet, it’s another family of distance measures that has showed signicant improvements in
GAN training stability: integral probability metrics (IPMs)[129]. Given F a set of functions from
X to R, we can dene:
dF(Pr,Pθ) = sup
f∈F
Ex∼Pr [f(x)]− Ex∼Pθ [f(x)]
as an integral probability metric associated with the function class F . Depending on this
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function class, the expression of that distance measure can vary widely. e intuition being IPMs
is that they measure the distance between probability measures via the largest discrepancy in
expectation over a class of ”well behaved” witness functions.
e Wasserstein GAN [14] was the rst GAN model proposed with such an IPM, using the
Wasserstein-1 or Earth Mover (EM) distance:
W (Pr,Pg) = inf
γ∈Π(Pr,Pg
E(x,y)∼γ[||x− y||]
at can be translated using the Kantorovich-Rubinstein duality [193] into:
WF(Pr,Pθ) = sup
||f ||L≤1
Ex∼Pr [f(x)]− Ex∼Pθ [f(x)]
where f is the family of 1-Lipschitz functions f : X → R. Having it be the family ofK-Lipschitz
function does not maer because it would just multiply WF(Pr,Pθ) by K .
Enforcing this constraint in the GAN training is the hardest part, and the authors resolved to
clamping the weights of the neural network within a xed box (e.g., W = [−0.01, 0.01]l) aer
each gradient update. In their formulation, the discriminator becomes the critic, and they follow
the training algorithm described in Figure 1.11 where fw is the critic function and gθ the generator
function.
e WGAN claimed the following contributions:
• e discriminator can in theory be trained to convergence
• ere’s a correlation between the generator loss decrease and the quality of the output
• Mode collapse becomes more rare than with the regular GAN architecture
However, the way the WGAN enforced the K-Lipschitz requirements, using weight clipping,
seemed to still cause issues in the training process and the quality of the outputs. In response
to these issues, Gulrajani et al. [68] proposed a gradient penalty GAN, or WGAN-GP, showing
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Figure 1.11: Training algorithm of the Wasserstein GAN [14]
the issues with weight clipping and how a penalization of the norm of the critic gradient with
respect to its input addressed more eciently the Lipschitz requirement.









[(||∇x˜D(x˜)||2 − 1)2]︸ ︷︷ ︸
WGAN-GP gradient penalty
Where Px˜ is dened by sampling uniformly along straight lines between pairs of points sam-
pled from the data distribution Pr and the generator distribution Pg, motivation by the fact that
the authors demonstrated the optimal critic contains straight lines with gradient norm 1 con-
necting coupled points from Pr and Pg. e training algorithm of the WGAN-GP is described in
Figure 1.12.
e WGAN-GP objective function is considered to be the new baseline now in terms of GAN
models and it seems that no one uses the original GAN objective dened by Goodfellow et al.
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Figure 1.12: Training algorithm of the WGAN-GP [68]
[65].
GANs extensions and applications
Beyond the specics of which neural networks should be used in the discriminator (or critic) and
the generator, or what should be the objective function of the deep implicit generative model,
there are a number of variations around the GAN framework that yield novel applications of
interest for this thesis.
Conditional GANs e conditional GAN [125] is a simple extension of the original GAN





V (D,G) = Ex∼pdata(x)[logD(x|y)] + Ez∼pz(z)[log(1−D(G(z|y)))]
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where y can be any kind of auxiliary information such as class labels or data from other modali-
ties, and is simply concatenated to the real data x and the latent space vector z (Figure 1.13). It
ultimately allows to decide the class of samples generated by choosing the nature of the auxiliary
information that goes with the latent space random vector.
Figure 1.13: Conditional GAN structure [125]
e latest paper improving on the conditional GAN approach is the RoCGAN [37] or Robust
Conditional GAN, where the authors augment the generator with an unsupervised pathway to
encourage the outputs of the generator to span the target manifold even in the presence of large
amounts of noise.
Applications GANs have been used in many dierent elds:
• Computer vision:
– Image super-resolution [104],
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– Image blending [201],
– Art [180, 60, 54],
– De-blurring [97],
– Face completion [112],
– Face aging [12],
– Frontal view synthesis [83],
– 3D object generation in-painting, and reconstruction [194, 171, 203],
– Laplacian pyramid [45]
• Natural Language Processing:
– Text generation [70, 146, 208],
– Dialog generation [110],
– Neural machine translation [205]
and have been adapted to other data types beyond images and text:
• Discrete-valued structures: adversarially regularized autoencoders [115, 92, 36], Maximum-
Likelihood augmented GANs [29]
• Continuous-valued sequences: [126, 56]
Evaluating GANs: an ongoing challenge
e evaluation of GANs is a hard problem that takes its roots in statistics, with the two-sample
problem trying to measure the distance between two complex distributions. In ”Pros and Cons of
GAN Evaluation Measures”, Borji [26] compares all the methods that have been used so far, both
in general applications and for computer vision.
Borji recommendations about the desirable properties of a good GAN evaluation measure are:
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1. Be able to distinguish generated samples from real images,
2. Be able to identify mode drop and mode collapse, and detect overing,
3. Favor models that generate high delity samples,
4. Favor models that generate diverse samples,
5. Favor models with disentangled latent spaces,
6. Have well dened bounds (lower, upper, and chance),
7. Undermine trivial models such as the memory GAN,
8. Be sensitive to image distortions and transformations (for computer vision)
9. Agree with human perceptual judgments and human rankings of models,
10. Have low sample and computational complexity.
Two quantitative metrics currently standout in computer vision: the Fre´chet Inception Dis-
tance (FID)[72], and the Kernel Inception Distance (KID)[24]. ese two metrics rely on an Incep-
tion network trained to perform well on the ImageNet dataset image labeling task.[179] Instead
of comparing directly the synthetic and the real sample, the idea is to use the weights of these
data through the penultimate layer of the Inception network, and compare these weights. e
intuition is that such weights capture high level features similar to what the visual cortex would
identify as important image features.
e major dierence between these metrics is that FID uses Gaussian approximation of these
weights while KID calculates the Maximum Mean Discrepancy (MMD). Let pw(.) be the probabil-
ity of observing real data, and p(.) the probability of of generating model data. e FID d(., .) is
dened between the Gaussian with mean (m,C) obtained from p(.) and the Gaussian with mean
(mw, Cw) obtained from pw(.) given by:
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d2((m,C), (mw, Cw)) = ||m−mw||22 + Tr(C + Cw − 2 ∗ (CCw)1/2)
However, Sutherland et al. [24] demonstrated that there is no estimator of the FID which is
unbiased for all distributions, unlike the KID. KID is based on the powerful MMD metric designed
to address the very problem of two-sample test with kernels by Greon et al.[67].
e unbiased estimator of the squared MMD porposed by Greon et al. [67]:


















K(x, y) = k(φ(x), φ(y))
with φ the function mapping samples to their Inception representation




a polynomial kernel and d the representation dimension
GANs in healthcare
ere has been very few applications of GANs in healthcare so far. A recent review by Xiao et al.
[202] about deep learning in the EHR tried to enumerate papers involving GANs that use EHR
data but made a lot of approximations and mistakes.
e rst paper that used GANs to generated discrete data (i.e., categorical count or binary
matrices) was Choi et al. [35] with themedGAN model. e medGAN uses fully connected layers,
batch normalization and skip-connections. e ”trick” to generate discrete data (i.e., the counts
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and binary values) is to use an autoencoder. e autoencoder is trained on the real data and
the GAN is trained at generating the continuous weights of the middle layer of the autoencoder.
By doing so, there are no constraints on generating discrete variables for the GAN, a hard task
in these models, and the autoencoder regularized the GAN by transforming these continuous
values into the discrete output. e evaluation of the medGAN involved qualitative review from
a medical doctor, and a few quantitative metrics: dimension-wise probability with Bernoulli and
dimension-wise prediction with logistic regression.
e second most signicant paper is the Recurrent Conditional GAN or RCGAN by Esteban et
al. [55]. is GAN uses an LSTM architecture and works with a type of time series very dierent
from laboratory tests time series: high frequency ICU time series of regularly-sampled variables
measured by bedside monitors: oxygen saturation measured by pulse oximeter (SpO2), heart rate
(HR), respiratory rate (RR) and mean arterial pressure (MAP) from the Philips eICU database [8].
eir evaluation consist in the following tasks:
• Using toy datasets that can be visually evaluated
• Maximum mean discrepancy (MMD): they computed the squared dierence of the statistics
MMD2 between the two sets of samples xiNi=1, yjMj=1, and replace inner products between
























A lot remains unanswered regarding the use of implicit generative models in the EHR. e
medGAN model for discrete categorical variables was published before the leap in GAN model
that introduced Wasserstein and MMD objective functions and greatly improved the training pro-
cess. e RCGAN proposed an interesting approach to generate time series, but selected a specic
type of time series where there is no challenge in the representation and imputation/missingness
of the data. Finally, the focus of these GAN papers using EHR data has been mostly on privacy
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issues, therefore not leveraging the potential for simulating data and learning meaningful latent
representations that could be manipulated to operationalize the implicit learning.
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Chapter 2
Compare architectures and data
representations for laboratory test
forecasting
Laboratory test time series are complex EHR objects. I explained in the introduction chapter
why they are so valuable: they represent more than 75% of the structured data collected in the
EHR, are continuous data in their vast majority and present high reliability in terms of labo-
ratory to hospital transmission [137]. Moreover, laboratory tests are at the core of physicians
decision process[198] and can be indirectly tied to drug responses through a mechanism called
drug laboratory eect (DLE).
e overarching goal of this dissertation is to develop a generative model to simulate drug ef-
fects on laboratory test time series (LTTS). However, generative models are hard to evaluate (see
background) and they would not be the appropriate task to determine what are the architectures
that work with our data, and how to handle contextual features such as time or drug exposure
information. LTTS present four main challenges: (1) they are sequences of values, and therefore
we need to assess if sequential models present an advantage over models where features order
does not maer; (2) they are irregular sequences, and we know from the literature [140] that time
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paerns are meaningful, so we need to assess if time interval features improve performances;
(3) they are contextual data that do not exist in the vacuum: patients have many other types of
clinical data available – usually categorical data – and we can leverage drug exposure informa-
tion to help modeling drug responses; (4) they are usually non-stationary as there is a multitude
of perturbations, observed and latent, that aect their values, and therefore we need to either
address it, or select observation windows where the stationarity is satisfactory.
In order to address these challenges, this rst aim provides an evaluation framework for data
representation (i.e., how to handle temporal data with contextual auxiliary information), and
deep learning architectures (i.e., what are the architectures we should consider in the generative
adversarial networks (GANs) framework for aim 2). is framework is the supervised forecasting
of the laboratory test time series we want to later simulate. It consists of taking a time series of
length n, and predict the n + 1 value. It provides evaluation metrics in the form of various
errors we can compute that are intrinsic to the data we have, and enables us to incrementally add
complexity in both the model and the data representation.
To this end, I developed three experiments:
• First, only considering time series that are regularly sampled sequences, with one value per
day in order to have identical time intervals between measurements;
• en, adding irregularly sampled time series with time intervals as an additional variable
to integrate in our models
• Finally, considering irregularly sampled time series with only drug exposures as auxiliary
information.
e purpose of this aim is not to build the best forecasting model but to have a straightforward
supervised task to compare models. Each of these studies is associated with a dierent research
question, and this whole aim addresses them together as they are incremental steps toward the
same objective:
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Research question RQ1: How do deep learning models compare to classic machine
learning when it comes to forecasting regularly sampled laboratory test sequences?
Research question RQ2: How does the integration of time intervals in the forecasting
model aect performances?
Research questions RQ3: How can drug exposure auxiliary information improve
the forecasting task? How can this information can be integrated into deep learning
models? How do dierent drug exposure representations compare?
ese research questions will guide the discussion and conclusion of each sub-study of the
aim.
2.1 Material and Methods
2.1.1 Data selection
In the present study, I dened the data collection process that is common to all the studies in this
dissertation. All the data come from Columbia University Irving Medical Center/New York Pres-
byterian Hospital (CUIMC/NYPH) transformed for the Observational Medical Outcomes Part-
nership (OMOP) common data model (CDM) v5, including inpatient and outpatient records.
CUIMC/NYPH is an academic medical center with over 1000 inpatient beds serving both adult
and pediatric populations. e laboratories receive on average over 10,000 samples a day. Over
550 dierent assays are performed on-site in several laboratories, including Core (Hematology
and Chemistry), Microbiology, Molecular Diagnosis, Immunogenetics, Cytogenetics, and several
Specialty Laboratories and Satellite Laboratories. Over 15 million assays are performed annually
in-house. Due to the complexity of the cases treated at our hospital, over 200,000 assays and
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panels are sent to over 60 dierent outside reference laboratories every year.[95]
As of 2019, we worked with a structured database of 6.38 million patients that counts:
• 78.95 million drug orders, representing 40.76 million single ingredient exposures, for 1.41
million patients,
• 140.30 million diagnosis codes for 5.40 million patients,
• 64.38 million procedure codes for 3.58 million patients,
• 810.68 million measurements (i.e., laboratory tests and vitals) for 2.29 million patients.
I considered the patient visits as a unit of analysis, with about 38.49 million visit occurrences
recorded in our research database. I mapped each visit to the measurements performed through-
out its duration. Each laboratory test time series (LTTS) is therefore a time series of value from a
given laboratory test or vital, for a given patient, during a unique visit. Limiting these time series
to a visit versus considering time series for the whole patient medical history enables us to have
more reasonable time intervals and account for clinical events that are more relevant to the time
series at hand. e general statistics of unique time series length available during these visits are
displayed in table 2.1. at table has 3 main take aways: (1) vitals (i.e., respiratory rate, heart
rate, blood pressure…) are the most abundant measurements available but do not represent mea-
surements with the most time series. (2) the most abundant time series are for laboratory tests
that belong to the routine blood panels; (3) extreme values show that we are dealing with data
that can present errors when entered in the EHR or exported for research purpose, and quality
control is required.
Now that I have provided this overview of the data available in our EHR and the top-25 mea-
surements, I will focus on the data specic to each research question: regularly sampled labora-
tory tests, irregularly sampled laboratory tests, time intervals and drug exposures.
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2.1. MATERIAL AND METHODS
Regularly sampled time series
I restricted the sample set of laboratory test time series (LTTS) to the ones that have a regular
sampling to answer the rst research question. When multiple measurements were available
the same day, I averaged them. I explored the amount of data available in function of the wanted
length of time series (i.e., 5, 10 or 15 values) and the regular or irregular nature of sampling (Figure
2.1). I selected a time windows of 10 days which provides a good balance of number of features
available for modeling and amount of samples. We observe that the longer the time series, the
smaller the sample size, in particular for the most abundance measurements. When a given visit
has multiple time series candidates available, I took the earliest for consistency.
e regularly sampled laboratory test time series restricted to a 10-day length are charac-
terized in table 2.2. I computed the average dispersion (i.e., the ratio of the standard deviation
by the mean of each time series) for all laboratory tests to get a sense of the relative variance
of each measurement type. I selected glucose lab (LOINC 2345-7) as the main measurement to
be modeled throughout this dissertation, for its high dispersion, satisfactory number of samples
available, and link to various physiological processes. Urea nitrogen (LOINC 3094-0) was used
for validation, as another high dispersion laboratory test, and hematocrit (LOINC 20570-8) as a
low dispersion yet routinely collected laboratory test that should be easier to model.
Before training models on these time series, I proceeded to a quality control step for all lab-
oratory test to remove values outside of the 1-99 percentile range and remove extreme outliers
or spurious values that could arise at the various steps of data collection and mapping. A time
series with such values would be removed from the dataset. e nal counts and demographics
information are available in table 2.2. In addition, we can observe that the time series of these
three laboratory tests post quality control represent similar number of patients (glucose: 55,112;
urea: 58,804; hematocrit: 56,476) for comparable proportion of female patients (glucose: 45.08%;
urea: 45.51%; hematocrit: 46.34%) and average age at measurement (glucose: 58.35; urea: 58.29;
hematocrit: 59.23).
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LOINC Laboratory Name # time series Dispersion (Std)
2951-2 Sodium serum/plasma 85,626 0.032 (± 0.050)
2075-0 Chloride serum/plasma 85,614 0.043 (± 0.048)
3094-0 Urea nitrogen serum/plasma 85,600 0.273 (± 0.152)
2160-0 Creatinine serum/plasma 85,586 0.183 (± 0.133)
2345-7 Glucose lab 85,555 0.243 (± 0.141)
2823-3 Potassium serum/plasma 85,441 0.097 (± 0.053)
20570-8 Hematocrit 84,056 0.092 (± 0.049)
718-7 Hemoglobin 83,922 0.092 (± 0.048)
789-8 Erythrocytes [#/volume] in Blood 82,909 0.090 (± 0.048)
785-6 Erythrocyte mean corpuscular hemoglobin [Entitic mass] 82,892 0.019 (± 0.033)
787-2 Erythrocyte mean corpuscular volume [Entitic volume] 82,880 0.020 (± 0.027)
786-4 Erythrocyte mean corpuscular hemoglobin concentration [Mass/volume] 82,867 0.023 (± 0.029)
6690-2 Leukocytes [#/volume] in Blood 82,729 0.266 (± 0.187)
788-0 Erythrocyte distribution width [Ratio] 82,495 0.045 (± 0.093)
26515-7 Platelet count 82,352 0.247 (± 0.167)
17861-6 Calcium serum/plasma serum/plasma 80,667 0.053 (± 0.034)
28542-9 Platelet mean volume [Entitic volume] in Blood 77,582 0.102 (± 0.289)
2339-0 Glucose [Mass/volume] in Blood 62,774 0.192 (± 0.088)
8310-5 Body temperature 62,766 0.053 (± 0.065)
19048-8 Nucleated erythrocytes/100 leukocytes [Ratio] in Blood 62,231 0.931 (± 1.112)
Table 2.2: Summary statistics for top-20 laboratory tests when ltering for contiguous time series
of length days=10. e laboratory tests selected for modeling are highlighted in bold.
Blood Glucose (2345-7) Urea Nitrogen (3094-0) Hematocrit (20570-8)
Time series and Patient Counts
Time series 74,189 81,004 75,423
Patients 55,112 58,804 56,476
Sex
Male, n (%) 30,269 (54.92%) 32,044 (54.49%) 30,305 (53.66%)
Female, n (%) 24,843 (45.08%) 26,760 (45.51%) 26,171 (46.34%)
Age
Mean age (years), ± SD 58.35 ± 22.782 58.29 ± 22.749 59.23 ± 21.505
Race/Ethnicity
Caucasian/White, n (%) 11,874 (21.55%) 12,407 (21.10%) 11,843 (20.97%)
African American or Black, n (%) 4,051 (7.35%) 4,320 (7.35%) 3,971 (7.03%)
Hispanic/Latino, n (%) 5,455 (9.90%) 5,813 (9.89%) 5,305 (9.39%)
Asian, n (%) 590 (1.06%) 611 (1.03%) 575 (0.92%)
Other, unknown, multi-racial, n (%) 33,142 (60.14%) 35,653 (60.63%) 34,782 (61.69%)
Table 2.3: Post quality control ltering demographics for regularly sampled blood glucose, urea
nitrogen and hematocrit time series (days=10)
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I also computed the distribution of measurements for glucose lab in gure 2.2 (resp. gure
A.1 for urea nitrogen and A.12 for hematocrit in the appendix), a boxenplot to visualize the mean
and percentiles in gure 2.3 (resp. gure A.2 for urea nitrogen and A.13 for hematocrit), along
with a density heatmap of time series represented by their standard deviation and mean in gure
2.4 (resp. gure A.3 for urea nitrogen and A.14 for hematocrit).
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At least X values





Figure 2.1: Laboratory test time series above 10,000 samples, for 3 dierent lengths, and 2 types
of sampling.
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 distribution of the measurements - 10 days
Figure 2.2: Distribution of glucose lab measurements post-quality control for regular time series.
50 100 150 200 250 300 350
Glucose lab (2345-7)
 boxenplot of all measurements - 10 days
Figure 2.3: Boxenplot of glucose lab measurements post-quality control for regular time series
to visualize percentiles and potential outliers.
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Figure 2.4: Density heatmap of regular glucose lab measurements time series represented by
their standard deviations and mean.
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Irregularly sampled time series
For the second study, the goal was to assess whether or not time information is needed. e
dataset selected was composed of the laboratory tests from the previous study but with relaxed
time interval constraints. I selected time series of 10 values that can be spaced by more than one
day, producing a set of irregularly sampled time series but with an constant number of measure-
ments. ese irregular time series are shared between the second and third study of Aim 1, where
time intervals and drug exposures are evaluated respectively as additional features. In table 2.4
we can observe that relaxing the time interval constraints yields higher sample sizes, and that
hematocrit measurements are the most abundant time series available.
Similarly to the regular time series descriptive statistics, table 2.5 represent the demographics
of the three selected laboratory tests post quality control ltering, gures 2.5,2.6 and 2.7 represent
the distribution of measurements, boxenplot, and density heatmaps of the glucose lab irregular
time series (resp. gures A.4,A.5 and A.6 for urea nitrogen, and gures A.15,A.16 and A.17 for
hematocrit). e heatmap of average time intervals per time series for irregualar glucose lab
measurements is available in gure 2.8. Higher average time intervals are observed mostly for
low density areas of the heatmap due to the fact that the vast majority of the time series are
regular. A comparable eect can be observed for urea nitrogen in gure A.7, although with a
broader range of time intervals, and hematocrit in gure A.18.
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LOINC Laboratory Name # time series Dispersion (Std) Time interval (Std)
20570-8 Hematocrit 120,205 0.093 (± 0.051) 1.271 (± 2.821)
718-7 Hemoglobin 120,107 0.093 (± 0.051) 1.271 (± 2.816)
789-8 Erythrocytes [#/volume] in Blood by Automated count 119,278 0.091 (± 0.050) 1.276 (± 2.839)
785-6 Erythrocyte mean corpuscular hemoglobin [Entitic mass] 119,261 0.021 (± 0.037) 1.276 (± 2.838)
787-2 Erythrocyte mean corpuscular volume [Entitic volume] 119,254 0.022 (± 0.031) 1.276 (± 2.839)
786-4 Erythrocyte mean corpuscular hemoglobin concentration [Mass/volume] 119,251 0.023 (± 0.031) 1.276 (± 2.838)
6690-2 Leukocytes [#/volume] in Blood 119,243 0.264 (± 0.175) 1.277 (± 2.839)
788-0 Erythrocyte distribution width [Ratio] 119,007 0.047 (± 0.094) 1.278 (± 2.842)
26515-7 Platelet count 118,848 0.244 (± 0.165) 1.278 (± 2.845)
28542-9 Platelet mean volume [Entitic volume] in Blood 114,687 0.096 (± 0.266) 1.309 (± 2.892)
3094-0 Urea nitrogen serum/plasma 114,337 0.283 (± 0.156) 1.190 (± 2.400)
2160-0 Creatinine serum/plasma 114,329 0.184 (± 0.131) 1.190 (± 2.406)
2951-2 Sodium serum/plasma 114,324 0.031 (± 0.050) 1.190 (± 2.430)
2075-0 Chloride serum/plasma 114,303 0.042 (± 0.048) 1.190 (± 2.435)
2345-7 Glucose lab 114,248 0.248 (± 0.145) 1.188 (± 2.432)
2823-3 Potassium serum/plasma 114,144 0.100 (± 0.056) 1.190 (± 2.437)
17861-6 Calcium serum/plasma serum/plasma 107,956 0.054 (± 0.034) 1.194 (± 2.360)
19048-8 Nucleated erythrocytes/100 leukocytes [Ratio] in Blood 84,787 0.917 (± 1.114) 1.233 (± 3.034)
30392-5 Nucleated erythrocytes [#/volume] in Blood 83,879 0.711 (± 1.059) 1.233 (± 2.717)
19123-9 Magnesium [Mass/volume] in Serum or Plasma 81,994 0.107 (± 0.061) 1.242 (± 1.569)
Table 2.4: Summary statistics for top-20 irregularly sampled laboratory tests when ltering for
total length=10. e top-5 laboratory tests with the highest dispersion index are highlighted.
Blood Glucose (2345-7) Urea Nitrogen (3094-0) Hematocrit (20570-8)
Time series and Patient Counts
Time series 98,418 106,710 106,571
Patients 69,701 73,947 75,289
Sex
Male, n (%) 37,715 (54.11%) 39,777 (53.79%) 39,751 (52.80%)
Female, n (%) 31,986 (45.89%) 26,760 (46.21%) 35,538 (47.20%)
Age
Mean age (years), ± SD 57.51 ± 23.906 57.33 ± 24.038 58.58 ± 22.531
Race/Ethnicity
Caucasian/White, n (%) 13,982 (20.06%) 14,537 (19.66%) 14,389 (19.11%)
African American or Black, n (%) 5,034 (7.22%) 5,300 (7.17%) 5,190 (6.89%)
Hispanic/Latino, n (%) 6,925 (9.94%) 7,335 (9.92%) 6,945 (9.22%)
Asian, n (%) 690 (0.99%) 715 (0.96%) 676 (0.91%)
Other, unknown, multi-racial, n (%) 43,070 (61.79%) 46,060 (62.29%) 48,089 (63.87%)
Table 2.5: Post quality control ltering demographics for irregularly sampled blood glucose, urea
nitrogen and hematocrit time series (days=10)
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 distribution of the measurements - 10 days
Figure 2.5: Distribution of glucose lab measurements post-quality control for irregular time se-
ries.
50 100 150 200 250 300 350
Glucose lab (2345-7)
 boxenplot of all measurements
Figure 2.6: Boxenplot of glucose lab measurements post-quality control for irregular time series
to visualize percentiles and potential outliers.
58
2.1. MATERIAL AND METHODS
1 23 45 67 89



















Figure 2.7: Density heatmap of regular glucose lab measurements time series represented by
their standard deviations and mean.
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Figure 2.8: Time intervals heatmap of regular glucose lab measurements time series represented
by their standard deviations and mean.
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Drug exposure information
For the last study, the laboratory test data were the same time series with irregular sampling
from the previous study and I added drug exposure information. For each time series, I collected
the drug at the ingredient level (i.e., referenced by RxNorm) that had a drug era overlap with the
measurements.
Drug eras were dened at the ingredient level using the denition of the OMOP CDM: they
are extrapolated from drug exposures with a persistence window of 30 days, meaning that pre-
scriptions with a gap lesser or equal to 30 days belong to the same drug era (Figure 2.9).
Figure 2.9: Construction of drug eras in the OMOP CDM
e Anatomical erapeutic Chemical (ATC) classication system [1] is a hierarchical ter-
minology controlled by the World Health Organization Collaborating Centre for Drug Statistics
Methodology (WHOCC) to group drugs (Table 2.6). I mapped these RxNorm codes to their ATC
counterparts. is RxNorm to ATC mapping is one-to-many, but it presents the advantage of
enabling hierarchical grouping.
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ATC categories represent dierent granularity levels: therapeutic subgroups (second level),
therapeutic/pharmacological subgroup (third level), and chemical/therapeutic/pharmacological
subgroup (fourth level), a granularity that resembles the most drug classes. I focused on the third
(ATC-3), fourth (ATC-4) and h level (ATC-5, ingredient level similar to RxNorm).
Code Contents
A Alimentary tract and metabolism
B Blood and blood forming organs
C Cardiovascular system
D Dermatologicals
G Genito-urinary system and sex hormones
H Systemic hormonal preparations, excluding sex hormones and insulins
J Anti-infectives for systemic use
L Anti-neoplastic and immunomodulating agents
M Musculo-skeletal system
N Nervous system




Table 2.6: First level of the Anatomical erapeutic Chemical (ATC) classication system
For each of the four representations, I performed a two-sample Kolmogorov-Smirnov test to
assess how dierent the distributions of the means of the LTTS were between the exposed and
non-exposed groups. I ranked them by p-value, adjusted for multiple hypothesis testing since
we re-use samples between the dierent tests, and KS statistics. e drug exposure vector was
therefore built using the 5 or 10 most signicant drugs for each of the four representations: ATC-
3 (Table 2.7), ATC-4 (Table 2.8), ATC-5 (Table 2.9) and RxNorm (Table 2.10). Similar tables are
available in the Appendix for urea nitrogen (Tables A.1, A.2, A.3 and A.4) and hematocrit (Tables
A.5, A.6, A.7 and A.8).
In addition, I characterized the drug exposure relationship with the laboratory test time series
by representing the density heatmaps of time series exposed to the top-10 drugs according to the
KS test, for each drug representation (Figures 2.10, 2.11, 2.12 and 2.13). Similar gures are available
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in the Appendix for urea nitrogen (Figures A.8, A.9, A.10 and A.11) and hematocrit (Figures A.19,
A.20, A.21 and A.22). It is important to note that these heatmaps show that some drug concepts
are never occurring by themselves and always in combination with another top-10 drug concept.
Moreover, the center of gravity of these distributions is usually higher in mean and standard
deviation than the time series exposed to none of the top-10 drug concepts.
is study evaluated for each lab test the most predictive drug representation, along with
comparing dierent forecasting models.
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time series variance
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time series variance
C10A
(b) Time series non-exclusively exposed to one
of the top-10 ATC-3 concepts.
Figure 2.10: Density heatmap of irregular glucose lab time series exposed to the top-10 ATC-3
concepts ranked by KS statistics.
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time series variance
A10AF
(b) Time series non-exclusively exposed to one
of the top-10 ATC-4 concepts.
Figure 2.11: Density heatmap of irregular glucose lab time series exposed to the top-10 ATC-4
concepts ranked by KS statistics.
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time series variance
A10BB12
(b) Time series non-exclusively exposed to one
of the top-10 ATC-5 concepts.
Figure 2.12: Density heatmap of irregular glucose lab time series exposed to the top-10 ATC-5
concepts ranked by KS statistics.
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time series variance
insulin (human)
(b) Time series non-exclusively exposed to one
of the top-10 RxNorm concepts.
Figure 2.13: Density heatmap of irregular glucose time series exposed to the top-10 RxNorm
concepts ranked by KS statistics.
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2.1.2 Forecasting methods
General Approach
In this rst aim, I used a forecasting task to compare machine learning and deep learning models,
and dierent data representations for the laboratory test time series. For each time series of 10
values, the rst nine values where used as features, and the last value was used as the target
of the regression. I randomly split each dataset between a training set (90%) and a testing set
(10%). I kept for each dataset a consistent split between analogous experiments: the regular time
series regression study has the same train/test split as the generative adversarial networks (GANs)
experiment on regular time series, and the irregular time series dataset are the same between the
regression and the conditional GAN models for consistency between Aim 2 and 3.
e data were pre-processed by truncating at the 1 and 99 percentiles for quality control
to get rid of extreme or spurious values, and then scaled between 0 and 1. Time series with
measurements that did not respect these criteria were removed entirely.
For every model, I tuned the hyperparameters with cross-validation on the training set: for
machine learning models I used a 10-fold cross validation where a 10% random validation set is
taken from the training set to choose the best performing hyperparameters. e deep learning
models experimental pipeline is described in details in the next section. Once the hyperparame-
ters of a model are set, the model is trained on the complete training set, and evaluated once on
the testing set.
All the regression models rely on a mean square error loss function as preliminary studies
showed that it was the best objective loss with regard to testing evaluation metrics.
e main evaluation metrics of this forecasting tasks were the MSE and the mean absolute
loss (MAE). While the former emphasizes the larger errors, the laer provides a beer idea of the
error in real units of the measurement.
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where y is the true value and yˆ is the predicted value.
Deep learning experimental pipeline
Deep learning models require a more extensive hyper-parameter tuning. While their exibility
and capacity make them extremely powerful universal non-linear approximators, it comes at the
cost of having to explore very large hyper-parameter spaces. I designed an experimental pipeline
that balances breadth of hyper-parameters exploration, and depth of model exploration.
For each deep learning model, I rst ran a large amount of experiments with a limited amount
of epochs (i.e., 50 epochs or less), determined model by model to be sucient to observe a plateau
in the training and validation loss. for these general tuning experiments, the MSE loss is computed
on the training set and validation set (as described in the previous section), and the testing set is
held out until the very end of the process.
Following the general tuning, I selected the 10 models that have the lowest validation loss
averaged over the second half of the epochs. ese models were then re-run for 100 epochs, 10
times each with dierent random seeds to compute more robust estimates of the performances of
these models: this is the ne tuning step. Based on these estimates, I selected the model (i.e., hyper
parameters set) and the epoch that had the best validation loss averaged over the 10 separate runs.
Finally, during the testing step I ran the selected model for the number of epochs determined
with ne tuning on the whole training set and computed MSE and MAE on the test set with
the nal model. is step was repeated 10 times to account for the stochastic nature of neural
network training and produce estimates of the MSE and MAE.
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Regular time series: Models
Baseline and machine learning models Oen, deep learning models are evaluated rel-
atively to one another without baseline. A number of misconceptions have resulted from these
approaches that omit to compare advanced models with naive approaches and classic machine
learning algorithms. For these forecasting experiments, I set the naive baseline to be a ”repeat”
prediction: this heuristic predicts the next value to be identical to the last value of the time series
used for training.
I then selected two popular machine learning algorithms: linear regression, and random forest
regression [27]. While the former is considered to be the simplest approach, generalized linear
models (GLMs) have proven to be hard to beat in numerous prediction problems. Random forest
regression illustrates in comparison the performances of an ensemble methods relying on bagging
(i.e., bootstrap aggregation) built on the decision tree algorithm.
Deep learning models e rst deep learning model to be evaluated was the multi-layer
perceptron (MLP), a fully connected neural network that sets the baseline for deep models. e
architecture was selected as follow:
• First layer:
– Fully-connected layer (I,N)
– Batchnorm
– Leaky ReLU activation
• Middle layers (optional):
– Fully-connected layer (N,N)
– Batchnorm
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– Leaky ReLU activation
• Last layer
– Fully-connected layer (N,N)
– Batchnorm
– Leaky ReLU activation
– Dropout
– Fully-connected layer (N, 1)
Where N is the width of the network, and I is the size of the input. For simplicity of tuning,
the network width was constant once set for all layers except for the input and output layers that
follow the structure given above (Figure 2.14).
Due to the sequential nature of the input, I compared MLP to long short-term memory (LSTM)
cells.
e LSTM architecture [74] is a type of RNN that models both short and long term depen-
dencies in data. LSTM tries to solve the vanishing gradient problem by not imposing any bias
towards recent observations, but it keeps constant error owing back through time.
e LSTM regressor I evaluated had the following general structure: an LSTM network, fol-
lowed by a fully connected layers with BatchNorm, Leaky ReLU activation and Dropout, and a
fully connected layer without activation that computes the prediction, similar to the last layer of
the MLP model (Figure 2.15).
I evaluated dierent models of LSTMs where the hidden vector ht was used either completely
or at the last time step, where dropout between stacked layers was authorized or not, and where
the size of the fully connected layer following the LSTM network varied 2.11.
e last deep learning model evaluated was the convolutional neural networks (CNN), pi-
oneered by Yann LeCun in 1990 [102]. It consisted of two parallel CNNs with the following
structure:
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… … …
Figure 2.14: Multi-layer peceptron with time series input. Hidden layers are in grey, and the
output of the forecasting model is in blue. Every hidden layer has a Batchnorm layer, and leaky
ReLU activation function, and the last hidden layers contains a dropout mechanism.
• CNN 1:




– Conv1d: kernel size=2, padding=1
– BatchNorm (2 x scaleCoecient)
• CNN 2:
– Conv1d: kernel size=3, padding=0
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Figure 2.15: Long Short Term Memory (LSTM) architecture, where the LSTM cells are followed
by a fully connected layer with Batchnorm, leaky ReLU and dropout.
Dropout in LSTM* Hidden vector ht used Size fully connected layer (vs. hidden size)
Model 1 Yes Last 1x
Model 2 Yes Last 2x
Model 3 Yes All 1x
Model 4 Yes All 2x
Model 5 No Last 1x
Model 6 No All 1x




– Conv1d: kernel size=3, padding=1
– BatchNorm (2 x scaleCoecient)
e outputs of these two parallel CNNs were then concatenated and passed into a fully con-
nected layer stack similar to the last part of the MLP:
• Fully-connected layer(N,N)
• Batchnorm
• Leaky ReLU activation
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• Dropout
• Fully-connected layer(N, 1)
Where N is the size of the concatenated vector from the two parallel CNNs (Figure 2.16).
……
Figure 2.16: Convolutional Neural Networks (CNNs), where two CNNs with dierent lter sizes,
two and three, have their outputs concatenated and fed into a fully connected layer with Batch-
norm, leaky ReLU and dropout.
Irregular time series: Models
While regular time series were useful to get a baseline free of time interval variability by con-
trolling sampling rate, laboratory test time series are usually not regular as patients do not get
measurements every single day during their hospitalization. e frequencies vary between pa-
tients, and depend on the dierent stages of care. erefore it seems important to evaluate models
that can deal with these irregular time series. Another important aspect of these time series is
their context, in the form of all the other types of clinical events that occur during their time span,
such as diagnoses, procedures, or drug exposures. To this end, the previously introduced models
were adapted to add two types of auxiliary data: time intervals and binary drug exposures.
Time interval data were obtained by indexing measurements in days elapsed since the be-
ginning of the visit during which they were performed. I then computed the intervals in days
between two measurements as ∆(n) = t(n)− t(n− 1) where t(n) is the day index of the mea-
surement n and t(0) = −1.
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Drug exposures are represented by a binary vector that indicates if the patient was exposed
to the given drug concept during any of the days where the rst nine measurements (i.e., the
measurements used to train models) were performed.
Classic machine learning models and MLP integrated these auxiliary data by concatenating
them to the measurement features, directly at the input of the models. LSTM and CNN followed
a dierent approach. Time intervals were added as a second channel of features for LSTM and
CNN, as they are associated to measurements in a pair-wise fashion. erefore the input in these
cases went from 1x9 to 2x9. Binary drug exposure information are not specically associated to
a given measurement, therefore these data were concatenated at the output of the CNN module,
and LSTM module respectively, at the input of the nal stack of fully connected layers.
2.2 Results
2.2.1 Regular time series forecasting
Hyperparameter search
Hyperparameter search is the most time consuming part of training deep learning models. e
rst batch of experiments on regular time series is even more crucial that subsequent experiments
were based on them, in terms of hyperparameters such as batch size, learning rate, or networks
dimensions. ere is a subtle balance between the neural network (NN) capacity, its ability to
learn from the training set, usually represented by the training loss, and the generalizability of
the model evaluated with the validation loss. e general heuristic of these experiments was to
rst ensure that the models are learning, by trying to decrease the training loss as much as pos-
sible, and then use the validation loss to adjust regularization parameters. Regularization can be
performed through various methods. Some are borrowed directly from classic machine learning,
such as loss penalty (L1 or L2), and others are more specic to neural networks: gradient clip-
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ping, weight clipping, dropout, and even the imperfect estimates that arise from a BatchNorm
layer with a ”small” batch size. In these experiments, I used dropout always aer all the batch-
Norm layers [111] to follow recommendations on variance mismatch since these two processes
have dierent behaviors at testing and training times. I also tuned the L2 penalty on the loss, and
the batch size that has an indirect regularization eect.
Regression models can use a variety of losses, the most prevalent being the mean square error
(MSE) and the mean absolute error (MAE). I decided to use the MSE aer comparing the two losses
in preliminary experiments. e MSE has the advantage to penalized larger errors more than the
MSE.
In terms of optimization algorithms, I used the Adam optimizer and played with its β1 and β2
coecients that control the momentum of the rolling average computed over the gradient and
the square of the gradient respectively.
e complete deep learning pipeline was wrien for Python 3.7, and I used PyTorch 1.0.1 for
the deep learning library. Experiments were performed on both CPUs and GPUs clusters with
the following specications:
• A computation server with 64 CPU cores AMD Opteron 6272 - 322 Gb of RAM - 2 Tb of
storage
• A storage-oriented server with 40 CPUs core Intel Xeon CPU e5-2660 v2 @ 2.20 Ghz - 64
Gb of RAM - 37 Tb of storage
• A GPU server: 56 CPU cores Intel Xeon E5-2690 v4 @ 2.6 Ghz - 264 Gb RAM - 24 Tb of
storage - 4 NVidia P100 GPUs
e GPUs were used essentially for LSTM and CNN models where the speed gain was signif-
icant. For MLP, it was preferable to use a large number of CPUs rather than 4 GPUs given the
low speed gain they provide with these simpler models.
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Multi-layer perceptron (MLP) I started by training the MLP, rst exploring a broad range
of capacities. General trends showed that higher batch sizes (e.g., 128) and lower learning rates
(i.e., 5e-5) provide the best results. Hyperparameters such as leaky ReLU coecients and weight
decay (L2) varied in performances across congurations. High capacity networks tended to over-
t and width was preferable to depth (i.e., 3 layers of size 64 are beer than 7 layers of size 32).
e dierent rounds of experiments and their hyperparameters are described in table 2.12.
Parameters Round 1 Round 2 Round 3
Layers width 16, 32, 64, 128 32, 64, 128 64, 128
Number of layers 2, 3, 5, 7 2, 3, 5 2, 3
leakyReLU 1e-02 1e-1, 1e-2, 1e-3 1e-1, 1e-2, 1e-3
Dropout 0.0, 0.25, 0.50, 0.75 0.0, 0.25, 0.50 0.0, 0.25, 0.50
Batch Size 128, 64, 32 32 64, 128
Adam beta 1 0.9 0.0, 0.9 0.0, 0.9
Adam beta 2 0.999 0.999 0.999
Learning rate 1e-3, 1e-4 1e-4, 5e-4 5E-05
Weight decay (L2) 1e-2, 5e-3, 1e-3 1e-3, 1e-4 5e-3, 1e-3, 1e-4
Num. combinations 1152 648 432
Table 2.12: Hyper-parameters for MLP general tuning on regular glucose lab time series.
Long short-term memory (LSTM) I evaluated the 6 variations described in the methods
section by iterating over what worked beer from one round to the next, and learning from the
results of the MLP training. e hyperparameters of the LSTM experiments are gathered in table
2.13.
Convolutional neural network (CNN) With CNN, I also tuned the scaling coecient




Parameters Round 1 Round 2 Round 3
Models 1, 2, 3, 4 1, 2, 3 5, 6
LSTM hidden size 32 32, 64, 128 32, 64, 128
# of LSTM layers 1 1, 2 1, 2
leakyReLU 1e-1, 1e-2, 1e-3 1e-1, 1e-2, 1e-3 1e-2, 1e-3
Dropout 0.25 0.0, 0.25, 0.50 0.25, 0.50
Batch Size 32 32 32, 64, 128
Adam beta 1 0.9 0.0, 0.9 0.0, 0.9
Adam beta 2 0.999 0.999 0.999
Learning rate 1e-4 1e-4, 5e-5 1e-4, 5e-5
Weight decay (L2) 1e-2, 5e-3, 1e-3 1e-3, 1-e5 1e-3, 1e-4
Num. combinations 36 648 1,152
Table 2.13: Hyper-parameters for LSTM general tuning on regular glucose lab time series.
Parameters Round 1
MLP layers width 128, 512
leakyReLU 1e-2, 1e-3
Dropout 0.0, 0.25, 0.50
Batch Size 4, 64, 512
Adam beta 1 0.0, 0.9
Adam beta 2 0.999
Learning rate 1e-4, 5e-5
Weight decay (L2) 5e-3, 1e-3, 1e-4
Scaling coecient 4, 8
Num. combinations 864
Table 2.14: Hyper-parameters for CNN general tuning on regular glucose lab time series.
Fine tuning and Model Selection
Multi-layer perceptron (MLP) e 10 best MLP models aer the ne tuning step are rep-
resented in gures 2.17 and 2.18 with their training and validation losses average over 10 distinct
runs each.
e best MLP model for regular glucose time series had the following hyperparameters (Figure
2.19):




• Dimensions: 2 layers of width 64
• Leaky ReLU coecient: 1e-3
• Learning rate: 5e-5
• Weight decay: 1e-4
• Adam coecients: 0.0; 0.999
• Epochs: 90
I replicated these 10 experiments with urea nitrogen laboratory test (3094-0) (Figures A.23
and A.24), and the best performing model had the following hyperparameters (Figure A.25):
• Batch size: 128
• Dropout: 0.25
• Dimensions: 2 layers of width 128
• Leaky ReLU coecient: 1e-2
• Learning rate: 5e-5
• Weight decay: 1e-4
• Adam coecients: 0.0; 0.999
• Epochs: 87
Finally, these 10 MLP experiments for ne tuning with hematocrit (Figures A.33 and A.34)
resulted in the selection of a best model with exactly the same hyperparameters as urea nitrogen
at the exception of the number of epochs that was set to 95 (Figure A.35).
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Long short-termmemory (LSTM) LSTM showed more instabilities and noise over repli-
cations with dierent random seeds (Figures 2.20 and 2.21).
e best LSTM conguration (Figure 2.22) for glucose lab with regular time series was:
• Model: model #6
• Batch size: 64
• Dropout: 0.25
• Dimensions: 1 LSTM layer of hidden size 64
• Leaky ReLU coecient: 1e-2
• Learning rate: 5e-5
• Weight decay: 1e-3
• Adam coecients: 0.9; 0.999
• Epochs: 82
Replications with urea nitrogen (Figures A.26 and A.27), and hematocrit (Figures A.36 and
A.37) resulted in the selection of the same model for urea, with 84 epochs (Figure A.28) and of
the following model for the less volatile hematocrit time series (Figure A.38):
• Model: model #5
• Batch size: 32
• Dropout: 0.25
• Dimensions: 1 LSTM layer of hidden size 64
• Leaky ReLU coecient: 1e-2
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• Learning rate: 1e-4
• Weight decay: 1e-4
• Adam coecients: 0.0; 0.999
• Epochs: 82
Convolutional neural network (CNN) CNN training and testing losses showed similar
proles as MLP (Figures 2.23 and 2.24).
e best validated model (Figure 2.25) for glucose lab had the following hyperparameters:
• Batch size: 64
• Dropout: 0.0
• MLP stack size: 512
• Leaky ReLU coecient: 1e-3
• Learning rate: 5e-5
• Weight decay: 5e-3
• Adam coecients: 0.9; 0.999
• Scaling coecient: 8
• Epochs: 57
I validated the same 10 best model with urea nitrogen (Figures A.29 and A.30) and hematocrit
(Figure A.39 and A.40). Results were similar in terms of overall network capacity, with minor
dierences on other hyperparameters.
e best urea nitrogen model (Figure A.31) had the following hyperparameters:
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• Batch size: 64
• Dropout: 0.5
• MLP stack size: 512
• Leaky ReLU coecient: 1e-2
• Learning rate: 5e-5
• Weight decay: 5e-3
• Adam coecients: 0.9; 0.999
• Scaling coecient: 8
• Epochs: 86
And the best hematocrit model (Figure A.41) was:
• Batch size: 64
• Dropout: 0.25
• MLP stack size: 512
• Leaky ReLU coecient: 1e-3
• Learning rate: 1e-4
• Weight decay: 5e-3
• Adam coecients: 0.9; 0.999




Overall, we observe that MLP had the lowest capacity, with the highest training loss among
best selected models, but it managed to generalize well. e selected CNN model showed the
lowest training loss, and a validation loss on par with MLP. e selected LSTM model displayed
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I compared the forecasting performances of the machine learning and deep learning models to
the repeated measure baseline that assumes that the 10th value is identical to the 9th. While
this baseline resulted in a 1502.62 MSE (25.15 MAE), machine learning models outperformed it
with performances about 30% beer. Linear regression was the best machine learning methods
with an MSE of 1058.43. Among deep learning models, LSTM was on average worse than linear
regression, and at best performed the same. e MLP model had the best average MSE, lower
than the linear regression error by 3 points, and performing as well as 7 points lower than linear
regression. Finally, CNNs displayed MSEs that on average were very similar to MLP, with a best
performance about 1 point beer than MSE due to a larger variance (Table 2.15). e heatmap of
the regression MSE are illustrated in gure 2.26.
e forecasting results on urea nitrogen (Table 2.16) and hematocrit regular time series (Table
2.17) conrmed these trends: linear regression was the best machine learning model for hemat-
ocrit, but random forest regression dominated for urea nitrogen. MLP was the best model overall
and LSTM outperformed machine learning models for hematocrit but not for urea nitrogen. ere
MSE heatmap can be found in the Appendix section (Figures A.32 for urea nitrogen and A.42 for
hematocrit).
Model best MSE best MAE avg. MSE (±SD) avg. MAE (±SD)
Repeated (baseline) 1502.62 25.15 – –
Linear regression 1058.43 21.99 – –
Random Forest Regression 1083.69 22.45 – –
MLP 1051.11 21.85 1055.10 (± 3.328) 21.97 (± 0.069)
LSTM 1058.51 21.84 1065.92 (± 5.928) 22.17 (± 0.258)
CNN 1049.93 21.93 1055.63 (± 5.625) 22.04 (± 0.106)




Model best MSE best MAE avg. MSE (±SD) avg. MAE (±SD)
Repeated (baseline) 35.67 3.71 – –
Linear regression 34.80 3.71 – –
Random Forest Regression 34.39 3.75 – –
MLP 32.35 3.61 35.85 (± 1.353) 3.64 (± 0.019)
LSTM 34.80 3.80 35.85 (± 1.353) 3.89 (± 0.109)
CNN 33.15 3.69 34.49 (± 1.147) 3.77 (± 0.069)
Table 2.16: Evaluation of the forecasting model with regular time series for urea nitrogen (3094-
0)
Model best MSE best MAE avg. MSE (±SD) avg. MAE (±SD)
Repeated (baseline) 6.25 1.79 – –
Linear regression 5.53 1.72 – –
Random Forest Regression 5.68 1.75 – –
MLP 5.41 1.71 5.44 (± 0.017) 1.72 (± 0.005)
LSTM 5.47 1.72 5.58 (± 0.144) 1.75 (± 0.033)
CNN 5.43 1.72 5.48 (± 0.061) 1.73 (± 0.018)
Table 2.17: Evaluation of the forecasting model with regular time series for hematocrit (20570-8)
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repeat - training error repeat - testing error
linReg - training error linReg - testing error
RFR - training error RFR - testing error
MLP - training error MLP - testing error
LSTM - training error LSTM - testing error
CNN - training error CNN - testing error
Figure 2.26: Heatmap of the average training and testing MSE between forecasting models on
regular glucose lab time series.
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2.2.2 Irregular time series forecasting: Auxiliary time interval features
e goal of this study was two-fold: understand the impact of having irregularly spaced time
series instead of regular ones in terms of prediction performances, and answer the following
question: Is it necessary to integrate time interval features when the time window is limited to
the visit length?
Hyperparameter search
Multi-layer perceptron (MLP) For the rst experiments with time interval information,
I ran some preliminary experiments to evaluation the importance of scaling time intervals. Un-
scaled time intervals expressed in days would make models extremely unstable. Once this pre-
processing issue solved, I explored the hyperparameter space with an approach similar to the one
taken with regular time series (Table 2.18).
Parameters Round 1 Round 2
Layers width 32, 64, 128 32, 64, 128
Number of layers 2, 3, 5, 2, 3, 5
leakyReLU 1e-3 1e-1, 1e-2, 1e-3
Dropout 0.0, 0.25, 0.50, 0.75 0.0, 0.25, 0.50
Batch Size 32 64, 128
Adam beta 1 0.0, 0.9 0.0, 0.9
Adam beta 2 0.999 0.999
Learning rate 1e-4, 5e-5 5E-05
Weight decay (L2) 1e-3, 1e-5 5e-3, 1e-3, 1e-4
Num. combinations 288 972
Table 2.18: Hyper-parameters for MLP general tuning on irregular glucose lab time series with
time interval features.
Long short-termmemory (LSTM) Learning from the previous LSTM experiments, I used
two types of models: v1 and v2 which both have no dropout in the LSTM even when stacked.
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e former used only the last hidden vector, and the laer concatenated them all.
Parameters Round 1
Models time v1, time v2
Layers width 32, 64, 128
# of LSTM layers 1, 2
leakyReLU 1e-2, 1e-3
Dropout 0.25, 0.50, 0.75
Batch Size 32, 64, 128
Adam beta 1 0.0, 0.9
Adam beta 2 0.999
Learning rate 1e-3, 1e-4
Weight decay (L2) 1e-3, 1-e4
Num. combinations 1,728
Table 2.19: Hyper-parameters for LSTM general tuning on irregular glucose lab time series with
time intervals.
Fine tuning and selected model
Multi-layer perceptron (MLP) Even a visual inspection of the training and validation loss
of the 10 best MLP models with time interval features hint at a decreased performance (Figures
2.27 and 2.28).
e best validated MLP model had the following hyperparameters, with a lower capacity than
the best model for regular time series (Figure 2.29):
• Batch size: 32
• Dropout: 0.25
• Dimensions: 2 layers of width 32
• Leaky ReLU coecient: 1e-3
• Learning rate: 1e-4
97
2.2. RESULTS
• Weight decay: 1e-3
• Adam coecients: 0.9; 0.999
• Epochs: 55
e validation with urea nitrogen (Figures A.43 and A.44) and hematocrit (Figures A.52 and
A.53) showed that a 3 layers MLP of width 32 was the best performing model for both lab test,
with the following hyperparameters for urea (Figure A.45):
• Batch size: 32
• Dropout: 0.0
• Dimensions: 3 layers of width 32
• Leaky ReLU coecient: 1e-3
• Learning rate: 1e-4
• Weight decay: 1e-3
• Adam coecients: 0.0; 0.999
• Epochs: 93
and the following hyperparameters for hematocrit (Figure A.54):
• Batch size: 32
• Dropout: 0.0
• Dimensions: 3 layers of width 32
• Leaky ReLU coecient: 1e-3
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• Learning rate: 1e-4
• Weight decay: 1e-4
• Adam coecients: 0.0; 0.999
• Epochs: 56
Long short-term memory (LSTM) e LSTM training exhibited even more instabilities
with very noisy training and validation losses (Figures 2.30 and 2.31).
e best performing model (Figure 2.32) had the following hyperparameters, with high dropout
and using the entire hidden vector:
• Model: model time v2
• Batch size: 32
• Dropout: 0.75
• Dimensions: 2 LSTM layer of hidden size 64
• Leaky ReLU coecient: 1e-3
• Learning rate: 1e-4
• Weight decay: 1e-4




Convolution Neural Network (CNN) e best performing model (Figure 2.35) had the
following hyperparameters:
• Model: time v1
• Batch size: 64
• Dropout: 0.75
• Dimensions: fully connected layer of size 128 aer CNNs
• Leaky ReLU coecient: 1e-3
• Learning rate: 1e-4
• Weight decay: 1e-4
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CNN - irregular time series - best model





Integrating time intervals to the data representation yielded unexpected results. Machine learn-
ing and deep learning models still outperformed the baseline. With blood glucose, all deep learn-
ing models had lower best MSE except for LSTM, and MLP and LSTM had an average MSE of
1066.46 (± 7.683) and 1069.53 (± 2.214) respectively, higher than linear regression at 1064.70 of
MSE (Table 2.20). Interestingly, when running the best MLP selected for regular time series on
the irregular time series, without time interval features, called MLP-reg in the tables below, I ob-
tained lower MSE than the MLP using time intervals for blood glucose (MSE: 1053.20 vs. 1058.06)
and urea nitrogen (MSE: 32.14 vs. 33.66). For irregular hematocrit time series, selected for the
low dispersion, the best performing model overall was MLP with time intervals (MSE: 5.71) with
a large variance between runs (avg. MSE: 5.81 (± 0.084)).
When put in perspective with the regular time series without time intervals, there is a general
increase in forecasting error by adding the time interval information. Finally, the best model for
irregular blood glucose time series was the CNN model with a best performance at an MSE of
1049.49.
Urea nitrogen and hematocrit also displayed increased errors compared to the regular time
series models (Tables 2.21 and 2.22).
Model best MSE best MAE avg. MSE (±SD) avg. MAE (±SD)
Repeated (baseline) 1461.90 25.14 – –
Linear regression 1064.70 22.22 – –
Random Forest Regression 1084.54 22.59 – –
MLP-reg 1053.20 22.06 1056.34 (± 2.795) 22.15 (± 0.077)
MLP 1058.06 22.06 1066.46 (± 7.683) 22.30 (± 0.134)
LSTM 1067.45 22.10 1069.53 (± 2.214) 22.33 (± 0.149)
CNN 1049.49 21.91 1054.58 (± 2.838) 22.09 (± 0.106)
Table 2.20: Evaluation of the forecasting model with irregular time series for blood glucose
(2345-7) with time intervals.
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Model best MSE best MAE avg. MSE (±SD) avg. MAE (±SD)
Repeated (baseline) 38.91 3.86 – –
Linear regression 36.22 3.81 – –
Random Forest Regression 35.58 3.83 – –
MLP-reg 32.14 3.69 32.66 (± 0.325) 3.73 (± 0.027)
MLP 33.66 3.75 35.21 (± 1.792) 3.87 (± 0.099)
LSTM 34.57 3.82 35.28 (± 1.059) 3.90 (± 0.127)
CNN 32.71 3.73 33.53 (± 0.467) 3.79 (± 0.037)
Table 2.21: Evaluation of the forecasting model with urea nitrogen (3094-0) irregular time series
with time intervals.
Model best MSE best MAE avg. MSE (±SD) avg. MAE (±SD)
Repeated (baseline) 6.95 1.87 – –
Linear regression 5.97 1.79 – –
Random Forest Regression 6.03 1.81 – –
MLP-reg 5.87 1.78 5.89 (± 0.012) 1.79 (± 0.005)
MLP 5.71 1.76 5.81 (± 0.084) 1.78 (± 0.020)
LSTM 5.92 1.79 6.03 (± 0.100) 1.81 (± 0.023)
CNN 5.84 1.77 5.89 (± 0.038) 1.79 (± 0.007)




repeat - training error repeat - testing error
linReg - training error linReg - testing error
RFR - training error RFR - testing error
MLP - training error MLP - testing error
MLP - training error MLP - testing error
LSTM - training error LSTM - testing error
Figure 2.36: Heatmap of the average training and testing MSE between forecasting models on
irregular glucose lab time series with time intervals.
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2.2.3 Irregular time series forecasting: Auxiliary drug exposure features
Model selection and ne tuning
Multi-layer perceptron (MLP) In this study, I re-used the 10 best models from the regular
time series experiments. Only the ATC-3 with 5 drugs is featured in this section, with its ne
tuning (Figures 2.37 and 2.38) to get the best validated MLP model for glucose lab irregular time
series with auxiliary drug exposure features (Figure 2.39):
• Batch size: 128
• Dropout: 0.25
• Dimensions: 2 layers of width 64
• Leaky ReLU coecient: 1e-2
• Learning rate: 5e-5
• Weight decay: 1e-3
• Adam coecients: 0.9; 0.999
• Epochs: 100
e other ne tuning and selected model gures can be found in the Appendix A.4.1.
Forecasting results
Overall, adding drug exposure representations resulted in lower MSE than using only irregularly
sampled measurements. While time intervals were harming the performances, binary drug ex-
posure improves them for all the models tested. On average, MLP were the best models for every
drug representation. Adding drug exposures to the binary vector, from 5 to 10, did not improve
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the models except for ATC-5 (1039.97 vs. 1040.90 for best MSE) but each model was well within
each other’s standard deviation. e best drug representation was ATC-3 with 5 drug concepts,
illustrated with its MSE heatmap for 5 and 10 drugs in gure 2.40. e worse drug representa-
tion on average was surprisingly RxNorm with 10 drugs, while ATC-4 with 10 drugs and ATC-5
with 5 drugs were the worse models in terms of best possible performance (1045.55 vs. 1045.45
respectively). It is important to note that these models were however beer than the MLP with
time interval features (1058.06 MSE). e other heatmaps of training and testing errors can be










































































































































































































































































































































































































































































































































































































































MLP - irregular time series - best model
Figure 2.39: Best MLP model for irregular glucose lab time series with auxiliary drug exposure






features Model best MSE avg. MSE (±SD)
ATC-3
5
Repeated (baseline) 1463.61 –
Linear regression 1051.82 –
Random Forest Regression 1080.76 –
MLP 1039.97 1044.48 (± 2.963)
10
Repeated (baseline) 1463.61 –
Linear regression 1051.79 –
Random Forest Regression 1075.55 –
MLP 1040.90 1046.98 (± 4.125)
ATC-4
5
Repeated (baseline) 1463.61 –
Linear regression 1055.27 –
Random Forest Regression 1080.15 –
MLP 1044.10 1046.63(± 1.949)
10
Repeated (baseline) 1463.61 –
Linear regression 1052.64 –
Random Forest Regression 1072.78 –
MLP 1045.55 1047.71 (± 2.363)
ATC-5
5
Repeated (baseline) 1463.61 –
Linear regression 1057.28 –
Random Forest Regression 1080.88 –
MLP 1045.45 1048.78 (± 2.884)
10
Repeated (baseline) 1463.61 –
Linear regression 1054.62 –
Random Forest Regression 1073.09 –
MLP 1042.86 1047.87 (± 3.141)
RxNorm
5
Repeated (baseline) 1463.61 –
Linear regression 1056.04 –
Random Forest Regression 1080.90 –
MLP 1042.71 1046.74 (± 2.065)
10
Repeated (baseline) 1463.61 –
Linear regression 1054.40 –
Random Forest Regression 1073.87 –
MLP 1044.30 (1050.93 ± 4.956)
Table 2.23: MSE on test set of irregularly sampled blood glucose (2345-7) for dierent drug
representations and numbers of features
114
2.2. RESULTS
repeat - training error repeat - testing error
linReg - training error linReg - testing error
RFR - training error RFR - testing error
MLP - training error MLP - testing error
(a) ATC-3 with 5 drugs
repeat - training error repeat - testing error
linReg - training error linReg - testing error
RFR - training error RFR - testing error
MLP - training error MLP - testing error
(b) ATC-3 with 10 drugs
Figure 2.40: Heatmap of MSE errors by model for glucose lab irregular time series with ATC-3




Aim 1 was informative on several aspects. First, it was an extremely helpful series of studies to
calibrate the experimental pipeline and explore the hyperparameter space to get a sense of what
kind of hyperparameters work with these data, a rather understudied question up until now. It
also illustrated the diculty of balancing capacity and generalizability with deep learning models,
that constantly outperformed machine learning models. at being said, linear regression showed
extremely robust results and trained in a fraction of the time needed to tune, ne tune, and test
neural networks, showing that deep learning is a disputable approach for simple regression tasks.
However the goal was not so much the regression task but more the evaluation and compar-
ison of models. To that regard, I was able to get identify key challenges and draw some conclu-
sions. Although LSTMs and CNNs are in theory more appropriate to the sequential data than
MLP, MLP was oen superior and always faster to tune and train. CNNs displayed beer perfor-
mances than LSTMs in every experiment for all laboratory tests studied, and even outperformed
MLP for irregular glucose time series with time interval information. Moreover, LSTMs appeared
to be more unstable than any other deep learning model tested, and were extremely sensitive
to hyperparameter changes and data pre-processing. It is possible that LSTMs and CNNs would
have been more useful if the data selection processed had been slightly dierent: with the current
approach, time series are selected based on the earliest sequence of measurements available dur-
ing a given visit. It might cause the time series to span across similar processes of care. If I had
taken a mixture of time series from the beginning and from the end of the visits, models able to
deal with time variance and temporal similarities might have been superior to MLP that simply
takes features as being from comparable conditions. In terms of pure performances, these fore-
casting models performed decently, within ranges of what current models and experts achieve on
predicting glucose, although the data I used were much less granular than recent blood glucose
forecasting studies for type 2 diabetes patients [11].
Regarding the data representation, this aim demonstrated that time intervals did not help
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models, except for the low dispersion irregular hematocrit time series, and that drug represen-
tation had the best performances overall. It is entirely possible that at the scale of the visit the
time intervals available do not maer much and that they could play a valuable role if visits were
stitched together for a given patient, yielding intervals of months and not days. However, the cur-
rent results show the superiority of sequence time over clock time, a conclusion already drawn
by Hripcsak et al. [80] in a similar context of evaluating drug laboratory eects with lagged
regressions.
It also raises the question of the samples’ point of view. ese studies were conducted con-
sidering individual visit segments, and samples were randomized between training and testing.
In theory, it could create some information leakage if the same patients has time series in both
the training and the testing set and that the ones in the training set happen aer the ones in the
testing set. ere is on average 1.4 time series per patient for the three laboratory tests of interest,
but the high variability even within a single visit makes it unlikely that such leakages are actually
happening. However, moving to a patient-centered study vs. the current visit-centered seing
would like be an improvement.
Indeed, one of the key properties of CNNs and LSTMs is their ability to deal with sequences
of various lengths. rough this mechanism, we could build models that take complete visits, and
even more to a patient-centered point of view stitching visits together and dealing with larger
time intervals than the one in this aim. at kind of study design would make neural networks
that can deal with sequences more relevant.
Moreover, it is important to keep in mind these measurements were taken in the in-patient
seing, naturally biasing the population towards sicker patients and, for the benets of our ex-
periments, more frequent blood measurements. One of the drawback is that these laboratory test
time series are more likely to be dynamic than the ones of healthier patients with less measure-
ments over longer period of time.
On the purely technical aspect of training deep neural networks, some improvements could
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be explored: other optimization methods could be tested (i.e., stochastic gradient descent with
Nesterov momentum, RMSProp…), we could add random noise to the batches at training, other
activation functions could be experimented with, although sigmoid and tanh activations have
known issues regarding vanishing gradients and saturation, and other regularization methods
such as gradient and weight clipping could be implemented.
It was also valuable to see that the general order of performances of the models I compared
was usually consistent between laboratory tests that represent dierent biological processes and
had dierent mathematical and temporal properties. It is a demonstration of reproducibility that
could be extended not only to ther laboratory tests but also other medical institutions. In practice
though,
Drug exposures were valuable features in spite of their correlation with dierential eects
on laboratory tests as showed by the two-sample KS tested performed. Surprisingly, the most
abstract drug representation, ATC-3, yielded the best results. It could be explained by the trade
o between ne grained representations that suer from not having enough drugs represented
(i.e., RxNorm with only 10 drugs) compared to high level drug representation with a lot more
coverage of exposures. ATC-5 was the only representation that improved with 10 drug concepts
versus 5. We could conclude that the one-to-many mapping between Rxnorm and ATC-5 re-
sults in redundant features in the 5-concept representation, that can only be improved by adding
drugs that have independent drug exposures. Moreover, ATC-3 with the abstraction power of its
terminology probably adds more de-correlated information to the measurements than RxNorm.
e regression models could benet from the extensive literature on clinical data embedding to
integrate latent representation of drug exposures instead of their binary encoding. Aention
mechanisms could also benet the models to focus on specic segments of the time series and
specic drug concepts of exposures.
Finally, in terms of evaluating the forecasting models, we could have more clinically relevant
metrics, by taking into account the direction of the prediction (i.e., positive or negative) in ad-
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ditional of the error. is aim serves the purpose of evaluating data representations and deep
learning architectures for the generative adversarial networks introduced later, with an overar-
ching goal of clinical decision support. In this specic context, it does not just maer how far
from reality the prediction is, but if the prediction has the right trend, and if it crosses a clinically
signicant threshold that could inform decision making. Such metrics should be developed and
evaluated with physicians.
2.4 Conclusions
Aim 1 was designed to understand how deep learning can be applied to the data we wanted to
model, what were the data representation that carry the most information as evaluated by the
forecasting task, and what are the architectures that perform the best with these data representa-
tion. I demonstrated that MLP in the specic context of laboratory test measurements collected
at the visit scale was the most robust model in terms of capacity versus generalizibility trade-o.
Time intervals do not add information and therefore will not be used in the generative models as
auxiliary information. e validation laboratory tests presented similar results as blood glucose
which strengthen the validity of these conclusion.
On a more general note, when it comes to forecasting laboratory test time series with machine
learning, classic machine learning provides performances close to deep learning models results,








Deep generative models have recently encountered a renewed popularity with two novel ar-
chitectures: Variational Auto-encoders (VAEs) [93, 157], and generative adversarial networks
(GANs). While the former is a parametric generative model, the laer is an implicit genera-
tive model, therefore enabling the stochastic generation of samples without access to the learned
distribution parameters. GANs have been proposed in 2014 by Goodfellow et al. [65], piing two
deep neural networks against each other in a zero-sum game: a discriminator D classifying real
vs. synthetic samples, and a generator G mapping random noise to synthetic samples trying to
fool the discriminator.
While hundred of papers using the GAN framework have been published since 2014, mostly
in computer vision, very few studies have aempted to use these models on EHR data [55, 35].
Only one study has proposed a GAN architecture for medical time series [55]. However, this study
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focused on a specic type of medical time series: ICU vitals, characterized but a low availability
and a very high and regular frequency of sampling. ere is an obvious contrast with LTTS which
are more sparsely sampled but are available for orders of magnitude more patients.
In the meantime, the eld of deep generative models has matured, with studies from the ap-
plied mathematics community who brought their expertise in theories such as optimal transport
[192] to contribute more stable and ecient GAN models. More specically, the Wasserstein
GAN (WGAN) [69] with gradient penalty has become the new baseline when it comes to GAN
frameworks.
erefore, there are unique and unanswered challenge to modeling LTTS distributions with
generative adversarial networks, and opportunities in integrating drug exposures as auxiliary
information in conditional WGANs.
Research question RQ4: Can we learn complex distributions of laboratory test time
series (LTTS) using GANs?
Research question RQ5: Can we train conditional GANs to generate LTTS realisti-
cally correlated with drug exposures?
3.2 Material and Methods
3.2.1 Datasets
e datasets used for this Aim were the same as the ones described in the previous chapter, with a
focus on the glucose measurements. e WGAN in the rst study of this chapter used the regular
time series only, while the conditional WGAN of the second study used the irregular glucose time
series with the drug exposure features as the auxiliary information of the models.
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3.2.2 WGAN and conditional WGAN: model specications
e Wasserstein GAN algorithm implemented followed the recommendations of the original pa-
per on WGAN with gradient penalty [69], including the use of layer normalization in the critic
instead of batch normalization. e dierence between gradient and Lipschitz penalty [138] is
simply that the laer takes the maximum of zero or the gradient penalty, ensuring in eect that
the gradient penalty is always positive or null.
e conditional architecture was designed by translating the conditional GAN paper [125]
to the WGAN framework: the auxiliary information were concatenated with the random latent
vector at the input of the generator, to generate the time series. It was then concatenated again to
the produced time series, and to the real time series at the input of the critic, so that the critic also
computes the estimated Wasserstein-1 distance taking into account the auxiliary information –
particularly important for the generator’s training. Finally, I used RMSProp for the optimization
of the WGANs, following the recommendations of Gulrajani et al, and Petzka et al. [69, 138].
3.2.3 Evaluation metrics
Evaluating implicit models is a hard task. In computer vision, where human inspection can be
used as a sanity check, a dozen of dierent evaluation metrics have been proposed to compare
real and synthetic data and quantify how close the stochastically generated samples are from the
training data.[26] With EHR data, we do not have the luxury of visual inspection or highly en-
gineered computer vision networks, and expert evaluation by physician is both time-consuming
and arguably not precise enough to catch subtle dierences in very large datasets. More impor-
tantly, while computer vision benets from standard datasets such as MNIST [101], CIFAR-10[96],
CelebA[204], or ImageNet [44], biomedical data sciences do not have standard medical datasets,
mainly due to privacy and regulations.
Regardless, in spite of the absence of consensus regarding standard datasets, we must be able
to design quantitative evaluation metrics for implicit generative models of EHR data in a single-
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institution seing to begin with.
Intrinsic evaluations
In computer vision, a wide variety of evaluation methods have been proposed to evaluate the data
delity of synthetic images generated by GANs (see Background). Among them, an approach
starts gaining momentum: inception distances. Inception distance metrics rely on the Inception
Network, a heavily engineered convolutional neural network (CNN) designed to perform well on
image labeling for ImageNet [179]. e intuition behind inception distances is that the weights of
the penultimate layer of a deep neural network able to successfully classify images must pick up
features that are high level enough to mimic the way the human visual cortex would work. ere-
fore, Heusel et al. [72] proposed the Fe´chet Inception Distance (FID) by using the distribution of
weights of real and synthetic images owed through a trained Inception network.
Let pw(.) be the probability of observing real data, and p(.) the probability of of generating





for a basis f(.) spanning the function space in which p(.) and pw(.) live. this function f(.) is
replaced by the penultimate layer of an inception network trained on ImageNet and the result-
ing distributions of weights are approximated by multidimensional Gaussian to get the rst two
moments: mean and covariance. erefore, they used the Fre´chet distance [58] or Wassertein-2
distance [190] to dene the Fre´chet Inception Distance (FID) d(., .) between the Gaussian (m,C)
obtained from p(.) and the Gaussian (mw, Cw) obtained from pw(.) given by:
d2((m,C), (mw, Cw)) = ||m−mw||22 + Tr(C + Cw − 2 ∗ (CCw)1/2)
is quantitative evaluation metric for implicit generative models has shown good perfor-
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mance, and it has been translated to biomedical sciences for de novo drug design by Preuer et
al. [142] who designed an inception network called ChemblNet, a network trained to predict
bioactivities of about 1,300 assays from ChEMBL[23]. I used this Fre´chet distance to evaluate the
distance between the real and synthetic data generated by the GAN models I have trained, and
called it FID by analogy with the FID in computer vision, although no network played the role of
an inception network providing abstracted representation.
3.2.4 Extrinsic evaluations
In addition of the intrinsic metrics described in the previous paragraph, I used a train on synthetic
test on real (TSTR) approach to evaluate how well the synthetic data generated can retain the
information needed for the forecasting task, and how well it generalizes.
Other task-based predictions have been described by Razavian et al. [147, 149] and Che et
al. [30] using laboratory test time series for medical outcome prediction, and could be used as
alternative extrinsic evaluations of the synthetic data, compared to the real data. However, these
tasks are all classication tasks, while the forecasting task I describe is a regression, providing a
ner grained evaluation of the models and their impacts.
3.3 Results
3.3.1 Regular LTTS generation with WGAN-GP
Hyperparameter tuning
Despite using lessons learned from the MLP tuning in the previous aim, the WGAN hyperparam-




Parameters Round 1 Round 2 Round 3
Layers width 128 64, 128 128
Number of layers 2 2, 3 2, 3, 5
leakyReLU 1e-1, 1e-3 1e-1, 1e-2, 1e-3 1e-1, 1e-2, 1e-3
Dropout 0.25, 0.50 0.25, 0.50 0.0, 0.25
Batch Size 32 64, 128 32, 64, 128
Critic Update cycle 10, 5 10, 5 10, 5
Critic learning rate 1e-4, 5e-5 5e-5 1e-4, 5e-5
Generator learning rate 1e-4, 5e-5 5e-5 1e-4, 5e-5
Weight decay (L2) 1e-3, 1e-4 5e-3, 1e-4, 0.0 5e-3, 1e-4, 0.0
Lambda penalty 10, 5, 1 10, 5, 1 5, 1, 0.5, 0.1
Latent dimension 100, 10 100, 10 100
Num. combinations 384 1,728 5,184
Table 3.1: Hyper-parameters for WGAN general tuning on regular glucose lab time series.
I took the best performing hyperparameter combinations and tested them, adding gradient
penalty (GP) to the Lipschitz penalty (LP) (Table 3.2) used for the general tuning above.
Parameters Fine tuning
Layers width 128




Critic Update cycle 5
Critic learning rate 1e-4
Generator learning rate 5e-5
Weight decay (L2) 5e-3, , 0.0
Lambda penalty 1, 0.5
Latent dimension 100
Penalty type LP, GP
Table 3.2: Hyper-parameters for WGAN ne tuning on regular glucose lab time series.
Impact of sampling on FID
For each ratio of synthetic data, I generated 10 distinct datasets to get an estimate of the FID
and how much it varies. e FID values and their sub-components (i.e, dierence of the means
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and dierence of the covariance matrices) did not change signicantly depending on how much
synthetic data was generated to compute the distance. However, the standard deviation tended
to decrease as the amount of synthetic data increases, as expected (Figure 3.1).
FID evolution during training
e FID dropped within the rst 30 epochs or so, and then either stabilized, or showed signs of
overing of the WGAN with an upward trend toward epoch 80 (Figure 3.2). For reference, the
FID between the real training and the testing set was 15.22 (mean di.: 4.85, cov. di.: 10.37)
while the FID of the top 10 GAN model spanned from 26.71 to 46.26.
TSTR with an MLP forecasting model
I evaluated the 10 best WGAN models according to their FID with the TSTR extrinsic evaluation
(Table 3.3). We can see that the dierence in the covariance matrices was more correlated to
the TSTR metrics than the FID itself. e general trend is a relatively low error on forecasting
synthetic samples from the same generator, a higher error on the training data that the WGAN
was trained on, and the highest error on the testing set that the WGAN was never exposed to.
While the MSE on the testing set was above 1,100, it is not extremely far from the error from the
models trained on real regular time series in Aim 1. e GAN model that performed the best at
the TSTR task got an average MSE of 1120.84 (± 8.553), and a lowest MSE at 1103.84. Interestingly
enough, it was not the model with the lowest FID (39.88).
Density evolution through training of the best regular WGAN
By sampling every 5 epochs a synthetic dataset of the same size as the training dataset, we can
visualize the coverage of the synthetic data compared to the real training data it was ed on
(Figure 3.3). I also computed the weighted ratio of synthetic coverage. On every tile of the density



























































































































































































































































































































































































































































































































































































































































age), wrong (coverage of a tile not represented in the real data), and miss (absence of coverage
of a tile represented in the real data) (Figure 3.4). is barplot summarizes quantitatively the
heatmaps by epoch. We can observe that coverage increased fast and then plateaued around 30
epochs, to increase again past 70 epochs. e wrong ”modes”, synthetic time series that have
unrealistic summary statistic, decreased within the rst 30 epochs, and coverage improved aer
60 epochs. When observing the kernel density estimation plot, we see that the mean distribution
is approximated rst, and then the covariance is adjusted in order to cover the real distribution
beer during that second stage of the training. e best coverage reached was 88.22% and was





































































































































































































































































































































































































































































































































































































































































































































































Figure 3.3: Evolution of the synthetic density of time series for the best WGAN trained on regular
glucose lab time series, every 5 epochs.
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3.3.2 Irregular LTTS with auxiliary drug exposure generation with con-
ditional WGAN-GP
I then proceeded to train the conditional WGAN on the irregular laboratory test time series using
auxiliary drug exposures as conditional information. While generating realistic synthetic glucose
time series is a good rst step, the generation is only random due to the nature of GAN as implicit
generative models. We do not have any control over the mode of the generated samples, the
properties, or the sub-group to which these time series belong. Conditional GANs on the other
hand allow for known auxiliary information to be used during the training, at the input of the
generator and the critic. Once trained, the conditional GAN generator takes as an input a random
vector concatenated to an auxiliary information vector. While the former is useful for diversity in
the stochastic generation process, the laer enables the user to select the conditional information
of the time series generated and therefore direct this generation.
Hyperparameter tuning
Given the major similarities between the WGAN and the conditional WGAN, I only rerun the
10 best hyperparameter sets from the previous study. e model selection followed the same
process, at the dierence that I had to run these experiments for each drug terminology and
conditional vector length, similarly to the conditional forecasting model features of the previous
chapter: ATC-3, ATC-4, ATC-5 and RxNorm with 5 or 10 drug concepts. Because RxNorm with 5
drugs yielded the most realistic conditional WGAN, the gures illustrating the following analyses
are for that dataset only. e gures associated to the other drug terminologies and conditional
vector lengths can be found in the Appendix (Figures B.1, B.2, B.3, B.4, B.5, B.6, B.7).
Impact of sampling on FID
e same phenomenon than in the previous section was observed: the FID was stable through
sampling rate, and only the standard deviation of the FID decreased as the sample size of the
133
3.3. RESULTS
generated data increased (Figure 3.5). e real training set and the testing set had an FID of 11.04
(mean di.: 1.06, cov. di.: 9.98) while the FID with the synthetic data ranged from 15.67 to 43.26
across the various drug representation tested.
FID evolution during training
Similarly to the WGAN analysis, we observe that the covariance dierence is the main driver of
the FID, and usually decreases almost linearly, while the mean error is much lower and therefore
uctuates more with less impact on the total distance (Figure 3.6).
TSTR with a a conditional MLP forecasting model: evaluating dierent drug represen-
tations
Table 3.4 presents the best models in the TSTR task for each drug representation. e MSE on
the testing set spanned from 1088.36 for ATC-5 with 5 drugs, down to 1056.32 for RxNorm with
5 drugs, eectively performing as well as a linear regression trained on the real dataset with
RxNorm concepts for the top-5 drugs of exposure. ATC-5 with 5 drugs had the worst TSTR
score with its best MSE at 1088.36. e FID of these conditional GANs spanned from 17.46 for
RxNorm with 10 concepts, to 34.03 for ATC-3 with 10 concepts. For reference, the best non-
conditional model in terms of FID scored at 26.71. e synthetic samples from conditional models
were therefore overall more realistic, at the exception of ATC-3 with 10 concepts, and ATC-5
with 5 concepts. is might explain their high MSE in the TSTR task. While the best MSE with
non-conditional models was 1103.84, all the TSTR MSEs of the conditional models were between
1056.32 and 1088.36.
Density evolution through training of the best conditional WGAN
e best conditional GAN with 5 RxNorm concepts as auxiliary information presented an analo-



















































































































































































































































































































































































































































































































































































rst adjusted its mean, and then its variance and covariance (Figure 3.7). e analysis of the cov-




































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.7: Evolution of the synthetic density of time series for the best conditional WGAN























Figure 3.8: Weighted ratio of density categories covered by the best conditional WGAN trained




In this aim, I demonstrated that we can build generative adversarial networks able to generate
synthetic laboratory test time series that look like real data. I compared two dierent models: a
Wasserstein GAN with gradient penalty (WGAN-GP) to model regular glucose lab time series, and
a conditional WGAN-GP that uses the drug exposure representation introduced in the previous
aim to learn beer models, but also to control the drug exposure of the synthetic generated time
series.
I used two dierent quantitative methods to evaluate these models: an intrinsic metric called
the Frechet Inception Distance (FID) that consists of measuring the dierent of the mean and
covariance between the synthetic data and the real data; and an extrinsic evaluation that uses
the forecasting models developed in the previous aim to evaluate how well models trained on
synthetic data only perform on never seen before testing sets.
I rst studied the properties of the FID by comparing how the amount of generated data
impact the metric when it’s computed with a xed size training set the GAN was trained on. is
experiment showed that the generated data are very stable in spite of the stochasticity of the
implicit generative process. I then computed the FID and it’s two components (i.e., the mean and
the covariance dierences) across epochs to see how they evolve. It seems that most of the time
the covariance dierence is the main driver of the FID, and that the FID could be a good tool to
visualize overing of a WGAN model where the FID starts going back up.
I also added visual inspection of the data using the density heatmaps I have been generating
throughout this dissertation, to help understand how the density learned by the WGAN evolves
throughout epochs. It is important to note that all the GAN models developed in this aim had, in
spite of their similar mean and standard deviation densities, longer tails. ese models generated
more extreme values, including some negative measurements (i.e., unrealistic). It exposes one of
the main limitation of the Frechet distance that approximates Gaussians and is less sensitive to
these longer tails than kernel-based metrics such as maximum mean discrepancy (MMD). Sim-
141
3.4. DISCUSSION
ilarly to the forecasting model, these GANs could also benet from clinically relevant intrinsic
evaluation metrics, for instance comparing how real and synthetic data stand in terms of normal
ranges, or involving physicians in a qualitative expert evaluation.
e TSTR evaluation demonstrated that the covariance of the synthetic data has an enormous
weight on the generalizability of models trained on them. It is also important to note that the
performances obtained with synthetic data from conditional models are on-par with the perfor-
mances of models trained on real data, with an increased MSE that stays within performances
obtained with classic machine learning regression models.
Finally, while ATC-3 was a good drug representation for regression, RxNorm appears to be
the best conditional information to generate more realistic and generalizable synthetic glucose
lab time series. More importantly conditional GANs outperformed the non-conditional model in
spite of having to learn a more complex representation of the laboratory test time series.
Only one type of deep generative models, namely generative adversarial networks (GANs)
was used. ey are not the only types of deep generative models that could have been used.
While GANs are implicit models, Variational Autoencoders (VAEs), a type of prescribed model,
represent an alternative. Further investigation could be done using VAE, and hybrid models called
VAE-GAN [122]. Moreover, supervised models using LSTM have been the standard for sequence
generation[66], where text can be generated token by token by sampling from a distribution con-
ditioned on the previous token and a hidden representation of all the tokens already generated.
However there are known issues where the models have to sample from conditional distribu-
tions never seen at training and their solutions lead to models with no cost function specically
designed to encourage synthetic data delity.[98, 57] e GAN models of this aim present the
advantage of being self-supervised with a cost function, the Wasserstein distance, designed to
explicitly compute an estimate of the distance between real and synthetic samples.
Other auxiliary data could be used as conditional information, such as demographics (i.e., sex,
age, race/ethnicity) as they are known to have a direct impact of the laboratory tests distribution
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and dynamics. Such as conditional WGAN generating laboratory test time series based on de-
mographics, drug exposures, and other clinical covariates could be a module in a larger analysis
where these covariates are handpicked by the user for specic generation, or generated them-
selves stochastically using discrete GANs. With an increasing number of clinical variables, and
therefore an increased sparsity, methods to compress patient representations could be used to
improve the learning with large auxiliary datasets.
3.5 Conclusions
Aim 2 is the proof of concept that we can generate laboratory test time series from visits with
generative adversarial networks. ese synthetic time series are close to the real ones, and yield
on-par results when used to train forecasting models then tested on real data never seen by the
GAN. e conditional WGAN demonstrated two properties: conditional GANs generate higher
quality samples than non-conditional GANs, and they enable the targeted generation of synthetic
laboratory test time series exposed to drugs dened at the input of the generator.
In the next chapter, I explore further these properties to demonstrate applications of condi-
tional GANs on drug exposed laboratory test time series.
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Chapter 4
Simulate laboratory test time series with
WGANs and conditional WGANs
4.1 Introduction
Generative adversarial networks have produced impressive results in computer vision. Recent
papers have demonstrated that GANs can generate extremely realistic images [105] and there
are event websites inviting users to guess if the picture of an individual is real and synthetically
generated. However, one question is oen asked: What are GANs useful for?
e question might actually be easier to answer in the context of biomedical data science,
although a handful of broad themes have received particular aention lately in computer science.
Data augmentation, a method consisting of articially inating image datasets by adding copies
of the original images with noise, translations and rotations, is one of them. Oen, biomedical
datasets present class imbalances, and usually the sicker patients who are rarer to encounter end
up being the ones beneting the least from predictive models. GANs present the opportunity
of augmenting real datasets with selected synthetic samples that re-balance the classes to help
predict outcomes beer for these under-represented samples.
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Moreover, the conditional WGAN evaluated in the previous aim presents an additional ad-
vantage: we can now select the drugs of exposure, or any other clinical covariate that would be
added to the auxiliary information, to direct the data generation process. We need to investigate
if these models can generate realistic samples when the conditional information has never been
seen by the model during training. In other words: can the conditional WGAN generate realistic
laboratory test time series exposed to drug combinations that do not exist in the training set?
In this aim, my goal was to explore how deep generative models of laboratory test time series
can improve learning models, and how conditional WGAN can be used to simulate laboratory
test time series by selecting the drugs these time series are exposed to.
Research question RQ6: Can we use conditional LTTS WGANs for drug exposure
simulation?
Research question RQ7: How can LTTS WGANs augment real datasets to improve
performances in supervised learning?
4.2 Methods
e two main directions of this aim are: (1) the simulation of lab test time series by manually
selecting conditional drug exposure vectors, and investigating the interpolation power of these
model to infer the behavior of time series with conditional information not seen during training;
(2) the data augmentation task, where real datasets are augmented with synthetic data to improve
locally forecasting performances using the regressors from Aim 1.
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4.2.1 Inference power evaluation
In order to evaluate how well the conditional WGANs trained in the previous Aim 2 can infer sam-
ples from conditional class unseen at training, I designed the following experiments: I removed
from the training dataset glucose time series exposed to a unique drug, trained the GAN from
scratch on this new dataset, and then generated samples with single drug exposures to compare
them to real single-drug time series, and single-drug time series from the Aim 2 WGAN model
exposed to them at training. is experiment relies on the interpolation power of the latent space
in GANs. e two hypotheses tested in this evaluation are that conditional GAN can infer the
behavior of samples from other classes seen at training (i.e., even if the GAN has never seen drug
A alone, it has seen drug A in combination with other drug exposures), and that the latent space
can continuously interpolate these inferred samples. It means that we could for a given drug
of exposure generate all the states between its two binary states, 0 and 1, and get continuously
closer to samples exposed to the drug.
In order to evaluate the simulation of these time series, I used the Frechet Inception Distance
(FID) introduced in the previous chapter as a distance metric.
4.2.2 Data Augmentation by conditional generation
Aer analyzing the simulation properties of conditional WGANs, I investigated their usage for
data augmentation. If these models can infer unseen classes, or unseen combinations of classes,
they could inate specic sub-groups of samples in training sets to improve the performances of
the model at testing. In this second experiment, I rst augmented time series with unique drug
exposures and evaluated the performances of the MLP forecasting model from Aim 1 with these
new training datasets.
en, I targeted specic drug combinations that have low frequency in the training set, and
on which forecasting models yield high error on the testing set. ese are the most interesting
candidates for data augmentation, as they could benet from a high count in the training set to
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decrease their high testing errors.
4.3 Results
ese results were obtained using a conditional WGAN on irregular glucose time series with
drug exposures represented by RxNorm top-10 drugs, with the hyperparameters that yielded an
average FID of 17.46 (± 2.405) with real glucose time series.
4.3.1 Inferring glucose time series with drug exposures unseen at train-
ing
e original dataset contained 11,746 glucose time series exposed to a single drug at a time. ese
were removed from the training set that was le with 64,857 samples. the conditional WGAN was
trained with the hyperparameters that yielded the best FIDs in Aim 2, and the best model out of
10 runs was selected for the simulation experiment (FID: 22.31). Let’s call this conditional WGAN
the inference model.
For each of the 10 drugs, I generated 10,000 synthetic samples with a conditional vector incre-
mentally increasing between 0.0 and 1.0 by steps of 0.1 for that drug of interested, and computed
at every step the FID between these synthetic samples and the real samples only exposed to that
drug. In order to get FID ranges of reference, I also computed the FID between synthetic samples
and real single-drug samples using the conditional WGAN from Aim 2, that was exposed at train-
ing to samples with single drug of exposure (i.e., the exposed model). e FID between synthetic
and real samples at dierent interpolation values in the latent spaces are displayed in gures 4.1
to 4.10.
We observed two phenomenons: (1) sample sets generated along that interpolated condi-
tional exposure vector presented a continuously decreasing FID with the real data, showing the
interpolation power of the latent space in generative adversarial networks; (2) for all drugs, the
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model never exposed to single drug exposures got an FID close to the model that was trained with
single-drug exposure samples. Insulin detemir exposed time series were inferred by the inference
model with an FID comparable to the model that was exposed to it. ere was one outlying drug:
isopropanol, where our inference model samples were more realistic than the sample of the ex-
posed GAN that was trained on these single exposure time series. Table 4.1 summarizes the FID
between synthetic and real samples for the model exposed at training, and the model not exposed
at training.












Interpolation of TS exposed to insulin detemir
Figure 4.1: FID between synthetic and real glucose time series, for dierent values in the condi-
tional vector between 0, non-exposed, and 1, exposed to insulin detemir
For visualization purposes, I represented these single-exposure samples for the inference
model, the expose model, and the real data density represented by variance and mean of the
time series (Figures 4.11, 4.12).
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Interpolation of TS exposed to sitagliptin
Figure 4.2: FID between synthetic and real glucose time series, for dierent values in the condi-
tional vector between 0, non-exposed, and 1, exposed to sitagliptin
4.3.2 Targeted data augmentation with conditional WGANs
Now that we demonstrated that conditional WGAN can generate time series with conditional
information that was not seen at training, we built some condence about the ability of these
models to augment real datasets. Indeed, the ideal target for data augmentation are sub-groups
of samples that have low sample counts in the training set and high errors when the model is
applied on the testing set. We showed that conditional WGAN can simulate glucose time series
even when their belong to subgroups not seen at training, which should extend to time series
with very few samples at training.
As a rst experiment, I augmented the single drug exposure time series. ality control of
the input time series seemed to be very important in the data augmentation part when adding
synthetic data to real data. By applying the same criteria applied to the real data to the synthetic
data, forecasting performances dramatically improved between no quality control 4.2, and iden-
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Interpolation of TS exposed to insulin glargine
Figure 4.3: FID between synthetic and real glucose time series, for dierent values in the condi-
tional vector between 0, non-exposed, and 1, exposed to insulin glargine
tical quality control as in the forecasting experiments of Aim 1 with real data 4.3. Only drugs
1 (insulin detemir), 4 (insulin lispro) and 10 (insulin (human)) showed improvements when the
training set was augmented with simulated time series exposed to these drugs only.
I grouped irregular glucose time series by drug exposures (RxNorm, 10 concepts), and repre-
sented these groups by their count in the training set and the MSE on the testing set based on the
MLP forecasting model from Aim 1 (Figure 4.13).
In spite of the low number of samples for these combinations, augmenting these types of
glucose time series in the training set led to improved MSE in 7 out of 10 cases (Table 4.4).
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Interpolation of TS exposed to insulin lispro
Figure 4.4: FID between synthetic and real glucose time series, for dierent values in the condi-
tional vector between 0, non-exposed, and 1, exposed to insulin lispro
drug of exposure inference WGAN FID (± SD) exposed WGAN FID (± SD)
insulin detemir 6994.51 (± 173.328) 7221.17 (± 189.009)
sitagliptin 1770.57 (± 49.856) 589.87 (± 25.828)
insulin glargine 952.76 (± 76.363) 249.47 (± 11.458)
insulin lispro 5700.67 (± 84.937) 2094.06 (± 91.808)
metformin 643.97 (± 37.603) 249.45 (± 19.172)
isopropanol 1184.67 (± 61.595) 2051.22 (± 63.224)
glipizide 1127.71 (± 41.407) 478.10 (± 11.196)
glimepiride 2049.26 (± 55.207) 1757.40 (± 71.324)
glibenclamide 2099.16 (± 84.242) 1094.61 (± 41.500)
insulin (human) 359.62 (± 29.739) 66.40 (± 8.364)
Table 4.1: FID between real and synthetic data for exposure to a unique drug at a time: infer-
ence conditional WGAN never exposed to these single-exposure samples, and exposed conditional
WGAN that was trained with samples exposed to these unique drug exposures.
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Interpolation of TS exposed to metformin
Figure 4.5: FID between synthetic and real glucose time series, for dierent values in the condi-
tional vector between 0, non-exposed, and 1, exposed to metformin
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Interpolation of TS exposed to isopropanol
Figure 4.6: FID between synthetic and real glucose time series, for dierent values in the condi-
tional vector between 0, non-exposed, and 1, exposed to isopropanol
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Interpolation of TS exposed to glipizide
Figure 4.7: FID between synthetic and real glucose time series, for dierent values in the condi-
tional vector between 0, non-exposed, and 1, exposed to glipizide
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Interpolation of TS exposed to glimepiride
Figure 4.8: FID between synthetic and real glucose time series, for dierent values in the condi-
tional vector between 0, non-exposed, and 1, exposed to glimepiride
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Interpolation of TS exposed to glibenclamide
Figure 4.9: FID between synthetic and real glucose time series, for dierent values in the condi-
tional vector between 0, non-exposed, and 1, exposed to glibenclamide
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Interpolation of TS exposed to insulin (human)
Figure 4.10: FID between synthetic and real glucose time series, for dierent values in the con-
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Figure 4.11: Density heatmap of irregular glucose lab time series exposed to the top-10 RxNorm,
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Figure 4.12: Density heatmap of irregular glucose lab time series exposed to the top-10 RxNorm,





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4.13: Drug exposures represented by their count in gluocose time series in the training
set, and their MSE in the testing set using the best performing MLP forecasting model.
conditional drug vector # in training # in testing MSE in testing MSE w/ data augmentation
(1.0, 0.0, 1.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 1.0) 32 1 11754.32 7450.01
(1.0, 0.0, 0.0, 1.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0) 8 3 10769.26 7694.08
(0.0, 0.0, 1.0, 0.0, 1.0, 1.0, 0.0, 0.0, 0.0, 1.0) 14 1 10080.28 12973.09
(0.0, 0.0, 0.0, 0.0, 1.0, 0.0, 0.0, 1.0, 0.0, 1.0) 11 3 9711.61 9644.60
(0.0, 0.0, 1.0, 0.0, 0.0, 0.0, 1.0, 0.0, 1.0, 0.0) 5 1 8364.84 5846.65
(1.0, 0.0, 0.0, 0.0, 1.0, 0.0, 0.0, 0.0, 0.0, 0.0) 11 1 8231.11 11230.28
(1.0, 1.0, 1.0, 0.0, 1.0, 0.0, 0.0, 0.0, 0.0, 0.0) 2 1 7086.89 8151.28
(0.0, 1.0, 1.0, 0.0, 0.0, 0.0, 1.0, 0.0, 0.0, 1.0) 6 2 6345.81 3216.27
(1.0, 0.0, 1.0, 0.0, 0.0, 0.0, 0.0, 1.0, 0.0, 0.0) 5 2 6302.25 5368.03
(0.0, 0.0, 0.0, 1.0, 1.0, 0.0, 1.0, 0.0, 0.0, 1.0) 1 1 5895.70 4703.74





In the Aim 3, I showed the potential applications for conditional WGAN that can generate ir-
regular glucose time series based on a conditional vector of drug exposures. e two avenues
investigated were the inference ability of these generative models, directly tied to arithmetic
properties in the latent space of the generator network, and data augmentation in supervised
tasks.
In the rst study, one of the main limitation is the conditional WGAN used, along with the
drugs of exposure. is model was selected based on its overall performances at generating syn-
thetic samples close to the real data, and using the Frechet Inception distance. e FID is a good
metric to get a sense of the distance between gaussians approximated on two datasets, but not
ne grained enough for more thorough comparisons. is is where the maximum mean discrep-
ancy (MMD) metric, a kernel based distance, could be useful. Moreover, there are only 10 drugs in
the auxiliary information vector while this population was exposed to hundreds of them. Adding
drugs to the auxiliary vector, along with other clinical covariates as discussed in the previous
chapter would yield to a beer conditional WGAN and beer inference. However, most of the
inferred time series sub-groups were very close to the data generated by the WGAN that was
exposed to them at training.
In the data augmentation task, there was an obvious limitation with the sample size of the time
series groups in the testing set. A lot of them had only one sample, resulting in a very noisy and
sensitive MSE. Another diculty comes from the fact that the task is a regression task. Every data
augmentation study that has used GANs to improve supervised learning results was applied to
classication task. I do think that classication tasks are more robust to data augmentation than
regression, due to the more discrete process of selecting a decision threshold, versus a continuous
non-linear relationship between inputs and output in regressions. It would also be benecial to
compare the GAN-powered data augmentation with more classic data augmentation methods as
a baseline of comparison.
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Another limitation of this study was that only one laboratory test, blood glucose, was inves-
tigated. However it opens the way for subsequent studies to systematize the methods presented
here and rene them.
4.5 Conclusion
In this last chapter, I demonstrated useful properties of conditional WGAN to simulate drug ex-
posures on laboratory test time series. I showed that these generative models can infer samples
behavior based on latent space arithmetic when there is enough useful conditional information
available. I also showed that these simulated data can be used in specic tasks where sub-groups
of samples are under-powered, causing high errors in these sub-groups. While these studies are
only proof of concepts, they show promising applications that could directly impact how re-
searchers work with medical data, and provide the bases for next generation clinical decision




e contributions of this body of work concerned informatics, computer science, and precision
medicine. First, it constitutes a framework for using deep learning models with laboratory test
time series, and more generally, continuous medical time series with temporal and categorical co-
variates. Second, it demonstrates which generative adversarial networks architectures can learn
to generate laboratory test time series, and the advantages of conditional GANs in medicine. Fi-
nally, it investigates the properties of these generative models, and shows how simulating drug
eects on laboratory test time series can improve methods relying on these data, such as fore-
casting approaches and inference for rare cases.
In the rst aim, I established a framework to evaluate deep learning models based on labo-
ratory test time series with a forecasting task. e goal was to nd the most informative data
representation (i.e., how to represent the input data and which covariates should be included),
along with the models that would leverage these data the best. I rst worked with regular (i.e.,
evenly spaced in time) laboratory test time series (LTTS), showing that multi-layer perceptron
(MLP), the most basic architecture in deep learning, yielded the best performances. I then moved
to use irregular time series and showed that drugs of exposure were more informative features
than time interval, and that in spite of the good performances of convolution neural networks
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(CNNs), MLPs represented the most exible architecture for the specic protocol set for these
experiments.
In the second aim, I demonstrated that generative adversarial networks can be trained to
general realistic laboratory test time series. To do so, I used the Frechet inception distance (FID), a
distance based on approximated Gaussian distributions, as an intrinsic evaluation metric between
real and synthetic data to assess various models based on dierent , and used the forecasting task
from the rst aim as an extrinsic measure. I showed that Wasserstein GAN with gradient penalty
are reliable GAN models and that they were able to generate realistic synthetic LTTS. Since the
classic formulation of GANs do not let the direct the data generation process, I showed that
conditional WGANs enable the targeted generation of LTTS by selecting drugs of exposure, in
the form of auxiliary information present at training, and that the synthetic data generated with
these models was even closer to the real data than a non-conditional model. rough the train on
synthetic test on real (TSTR) extrinsic evaluation, I also showed that the generated synthetic data
were on par with real data when it comes to training forecasting models, and that conditional
WGANs produced even beer results than the simple WGANs.
Finally, I used these conditional WGANs to demonstrate that their can simulate drug eects
on laboratory test time series, with their inference and interpolation properties. By learning from
LTTS exposed to combinations of drugs, these models were able to isolate single-drug exposures
never seen during training and generate samples on par with models that were trained on single-
drug exposures. Beyond the simulation of drug eects on these laboratory test, I illustrated their
ability to simulate realistic data in the context of data augmentation by targeting drug combina-
tions that had the poorest forecasting results and showed that these training dataset mixing real
and synthetic data can yield beer results on the testing dataset.
As oen in biomedical informatics, the present studies have been conducted at a unique in-
stitution, Columbia University Irving Medical Center/New York Presbyterian, and could benet
from replications in other institutions. By making my code available, and initiating collabora-
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tions with other institutions, I hope that other medical centers will be able to replicate these
experiments, in particular the ones with conditional GANs as they constitute the most interest-
ing models for both research and clinical applications. Open sourcing code is one of the pillars
of the fast advances in machine learning and deep learning, and platforms such as Github enable
the widespread of novel models. However, since the biomedical eld is highly regulated with
regard to patients data, it is not possible to share pre-trained models or datasets. Indeed, a pre-
trained model could be reverse-engineered to extract information about the private training data.
e problem would be even more critical with the present generative models that actually gen-
erate real-looking clinical data. However, advances in dierential privacy could help share such
models between teams of researchers in a secured fashion while preserving patients privacy and
anonymity.
It leads us to the question of standards. As mentioned several times in this dissertation, elds
like computer vision or natural language processing have beneted tremendously from the avail-
ability of standard datasets to benchmark and evaluate models in computer science. Because of
the very nature of the data that we work with and Health Insurance Portability and Accountabil-
ity Act (HIPAA) regulations, producing standard medical or clinical datasets is a hard task, even
when the clinical data has been de-identied and dates have been shied given the inherent risks
of re-identication. However, datasets such as MIMIC III [89], an openly available dataset devel-
oped by the MIT lab for Computational Physiology, provide health data such as demographics,
vital signs, laboratory tests, medications, diagnosis codes, procedures, and other valuable longitu-
dinal variables for about 60,000 intensive care unit admissions. MIMIC III is probably the closest
data source that the biomedical informatics and biomedical data science communities have to
a standard dataset. It would be benecial that, as more and more biomedical researchers with
a computational training turn to deep learning,we derive from MIMIC standard sets of clinical
variables for specic supervised and unsupervised tasks that could be used in every paper for
evaluation and comparison of models. Generative models could also play a role, even more so
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with dierentially private approaches, to generate or provide generators of such data. ese gen-
erators could be trained in conjunction with phenotyping algorithms (i.e., algorithms used to
select patients based on specic clinical traits such as diseases or outcomes) to provide synthetic
cohorts generators restricted to specic phenotypes for a variety of studies.
Standard datasets could also help with the evaluation of generative models. While computer
vision has the Inception network, a highly engineered image classier, we do not have such easily
sharable trained model. e Inception network has been used for the evaluation of GANs where
the weights of the penultimate layer of this network are used as a high-level representation of
a given image dataset to compare real and synthetic images. We have yet to build similar high
level patient representation, or clinical data representation, that would embed domain knowledge
and learned features to compare real and synthetic clinical data with distance metrics such as the
Frechet distance or maximum mean discrepancy (MMD).
ere is a number of improvements that could bring these GAN models closer to production
level. Deep learning models are known to be data-hungry, and larger datasets could lead to
beer models. e previous discussion points about open sourcing code, collaborations, research
networks and standard datasets would enable the training of more diverse models. rough
examples in style transfer, we could also envision GAN models to be trained in a large medical
center, and then adapted to generate data that t a dierent population of patients with dierent
medical practices and biases, statistically speaking, to augment local datasets or be used in clinical
decision support (CDS) system. Research networks such as Observational Health Data Sciences
and Informatics (OHDSI) that has published a number of large scale studies such as the 250 million
patients study on treatment pathways [82] would be perfect candidates for large, dierentially
private, GAN training.
Beyond the dataset availability, some features of the GAN presented in this dissertation could
be further developed. is entire body of work was designed to simulate univariate laboratory
test time series, but we could design models to generate several laboratory test types simultane-
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ously. Laboratory tests are usually orders in batches, and there they have complementary and
supplementary eects. Rather than training a model for each laboratory test, we could train a
multivariate GAN model that generates whole panels and benet from the correlations and infor-
mation shared between the dierent measurements being modeled. One of the biggest challenge
would be dealing with missingness in the data, in the sense that dierent labs would have dier-
ent sampling paerns and would not necessarily always be measured together at the same date,
which poses an issue when aligning time series and feeding them synchronously to a neural net-
work. erefore research on dealing with missingness in neural networks inputs, with masking
mechanisms, and time interval information should be investigated further.
e time scale of these studies was limited, on purpose, to the visit horizon to aenuate the
non-stationary nature of laboratory test time series, and make sure that drug exposures were
current to the measurements. But a more mature model would have to juggle with short and
long-term time scales, especially in the case where we would consider a patient records of mea-
surements instead of a visit. While modeling time interval did not prove to be benecial in Aim
1, it could become a much more critical variable to represent and model with time intervals vary-
ing between days, months or years. As the time scale increases, more factors have to be taken
into account, both observed and latent, and sequential models such as CNN and recurrent archi-
tectures would have to be re-evaluated in this context. As previously discussed in Aim 1, such
models could also deal with time series of variable lengths, which is a key feature when it comes
to medical time series since sampling rates and time series lengths are highly variable between
patients.
I also restrained the types of covariates to drugs, and limited it to 10 drug concepts for clar-
ity and the need of baseline in this rather uncharted line of research. e conditional models
presented here could be extended to more covariates types like demographics, diagnosis and pro-
cedure codes, and more medication concepts. By adding more covariates, prior art regarding
regarding the compression of patient representation using dimension reduction or deep learning
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methods could become useful to avoid overing models due to the sparsity of these conceptual
representations. Moreover, the exposures have been modeled as binary variables. A ner grained
model could represent each drug by a binary vector over time, instead of just one binary variable,
and laboratory test dynamics could be explored, as patient would have varying exposures and
they could be then simulated by the GANs. at would in turn enable us to have models where a
user could generate the equivalent of self-controlled data with measurements for a given patient
being alternatively exposed and non-exposed to a given drug or combinations of drugs over time.
On the purely deep learning standpoint, there are of course other GAN models available than
the Wasserstein GAN used in this dissertation. Adversarial learning is a very active eld of re-
search, and applied mathematics researchers have been contributing heavily the past couple years
with models such as the MMD GAN. As discussed in Aim 2, other types of deep generative models
such as VAE or hybrid VAE-GANs could also be evaluated for the generation of medical time se-
ries. Generative adversarial networks are a framework, and it can t many types of architectures.
ese GANs could be used with neural networks other than the MLPs used here, depending on
the types of data being modeled and simulated. Multivariate GAN model could justify the use of
CNNs or multi-input multi-output LSTMs.
So what are the potential applications of such a system? First, I provided a proof of concepts
for inference of eects unseen at training and data augmentation, the laer being a consequence
of the former. Oen in medicine, the worst cases are also the rarest. But beyond that simple
observation, a lot of patients have unique trajectories preventing machine learning models from
being trained eciently to provide reliable predictions. In their multi-center international study,
Hripcsak et al. [82] found that in a population of 250 million patients, 10% of type 2 diabetes
patients, 11% of patients with depression, and 24% of patients with hypertension had a unique 3-
year treatment pathway. Conditional generative adversarial networks could provide a generative
tool to disentangle information and generate realistic isolated eects of treatments or sequences
of treatments absent or extremely rare in learning models’ training datasets. With their ability
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to learn conditional distributions, these GANs could be used with augment datasets for beer
predictive models, or be used as a patient simulator to go beyond simple patient matching to
help physicians in their decision making. We could envision conditional GANs that would take
a complete patient’s medical history including categorical variables such as demographics, med-
ications, diagnoses and procedures as auxiliary information, along with the variables specic to
the current visit. A physician could simulate drug combinations, and alternative treatment ef-
fects on a panel of laboratory tests, directly tapping into drug laboratory eects (DLE) to foresee
potential adverse drug reactions. ese simulations could even be fed into models that predict
clinical outcomes from laboratory tests, since GANs can generate as many samples as needed,
and therefore build beer estimates. Such a GAN system, with all the extensions listed in the
previous paragraphs would be able to deal with the many challenges inherent to clinical data,
and leverage the inference properties of conditional GANs at disentangling conditional eects
to infer correlations between the output and auxiliary input combinations unseen at training.
Data augmentation, as stated above, is a direct application of these properties, and GANs could
be used to inate subgroups of samples that learning models struggle to predict due do their low
count number. Of course, there is no information created, and GANs are limited by the amount
of information they were exposed to at training, However they seem to be able to ”share” this
information between possible scenarios represented by dierent combinations of auxiliary data
(i.e., drug exposures in this body of work). Further research needs to be done to understand the
eects of GAN-directed data augmentation and how deep learning models use the extra data,
and the change in the distribution of training samples to navigate the optimization of their loss
function and provide beer estimate for the rare augmented cases. It would also be important to
understand what are the drawbacks of this type of data augmentation as I observed that if MSE
improved for some augmented categories of type series, the average MSE did not change much.
Directly related to patient-level prediction, some GAN models such as BiGAN and ALI [49, 53]
have developed dierent methods to map real samples to their latent representation through
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the generator. ese reverse mapping methods could be applied to our conditional GAN that
generate laboratory tests or other medical time series. rough that process, we could nd what
latent representation, both in terms of the random noise and the auxiliary clinical information,
matches a given real patient. We could then modify the auxiliary variables that are actionable
(e.g., medications, dosages, procedures…) and see how the patients trajectory would be aected
by running this new latent vector through the trained generator. is kind of GAN model could
help the direct in-silico simulation of eects on trajectories of care, and would rely on all the
properties and features mentioned above.
Another interesting application could be the use of the critic network, usually not re-used
aer the adversarial training is done and the generator network has learned to approximate the
target distributions. e critic in the WGAN framework represent an approximation of a witness
function that helps compute a distance between real and synthetic samples. is witness function
could be used in an unsupervised anomaly detection system to measure the distance between the
data from the training set, and any other dataset never seen by the GAN. It could be used to learn
smarter conditional normal ranges based on demographics, treatments, and medical history and
detect when a laboratory test is abnormal without having to know how an abnormal laboratory
test looks like, but by just having trained on labeled normal measurements.
is dissertation has provided a framework for a more principled use of deep learning methods
with laboratory test time series, and has opened the way for deep learning-based simulation of
continuous medical time series with clinical covariates. e eld is still green for deep learning in
healthcare and many innovative models need to be experimented with, as fundamental sciences
need their applied counterparts to have a tangible impact. Deep generative modeling present
a very promising family of models that could help researchers and physicians get closer to the
objectives of precision medicine.
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Urea nitrogen serum/plasma (3094-0)
 distribution of the measurements - 10 days
Figure A.1: Distribution of urea nitrogen measurements post-quality control for regular time
series.
20 40 60 80 100
Urea nitrogen serum/plasma (3094-0)
 boxenplot of all measurements - 10 days
Figure A.2: Boxenplot of glucose lab measurements post-quality control for regular time series
to visualize percentiles and potential outliers.
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Figure A.3: Density heatmap of regular urea nitrogen measurements time series represented by
their standard deviations and mean.
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Urea nitrogen serum/plasma 
 distribution of the measurements - 10 days
Figure A.4: Distribution of urea nitrogen measurements post-quality control for irregular time
series.
20 40 60 80 100
Urea nitrogen serum/plasma (3094-0)
 boxenplot of all measurements
Figure A.5: Boxenplot of urea nitrogen measurements post-quality control for irregular time
series to visualize percentiles and potential outliers.
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Figure A.6: Density heatmap of regular urea nitrogen measurements time series represented by
their standard deviations and mean.
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Figure A.7: Time intervals heatmap of regular urea nitrogen measurements time series repre-
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C02D
(b) Time series non-exclusively exposed to one
of the top-10 ATC-3 concepts.
Figure A.8: Density heatmap of irregular urea nitrogen time series exposed to the top-10 ATC-3
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time series variance
C04AC
(b) Time series non-exclusively exposed to one
of the top-10 ATC-4 concepts.
Figure A.9: Density heatmap of irregular urea nitrogen time series exposed to the top-10 ATC-4
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(b) Time series non-exclusively exposed to one
of the top-10 ATC-5 concepts.
Figure A.10: Density heatmap of irregular urea nitrogen time series exposed to the top-10 ATC-5
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(b) Time series non-exclusively exposed to one
of the top-10 RxNorm concepts.
Figure A.11: Density heatmap of irregular urea nitrogen time series exposed to the top-10
RxNorm concepts ranked by KS statistics.
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 distribution of the measurements - 10 days
Figure A.12: Distribution of hematocrit measurements post-quality control for regular time se-
ries.
20 25 30 35 40 45
Hematocrit (20570-8)
 boxenplot of all measurements - 10 days
Figure A.13: Boxenplot of hematocrit measurements post-quality control for regular time series
to visualize percentiles and potential outliers.
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Figure A.14: Density heatmap of regular hematocrit measurements time series represented by
their standard deviations and mean.
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 distribution of the measurements - 10 days
Figure A.15: Distribution of hematocrit measurements post-quality control for irregular time
series.
20 25 30 35 40 45
Hematocrit (20570-8)
 boxenplot of all measurements
Figure A.16: Boxenplot of hematocrit measurements post-quality control for irregular time se-
ries to visualize percentiles and potential outliers.
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Figure A.17: Density heatmap of irregular hematocrit measurements time series represented by
their standard deviations and mean.
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Figure A.18: Time intervals heatmap of hematocrit lab measurements time series represented


























































B03A only J02A only















0 2 4 6 8
time series variance
S03A only









































































0 2 4 6 8
time series variance
S03A
(b) Time series non-exclusively exposed to one
of the top-10 ATC-3 concepts.
Figure A.19: Density heatmap of irregular hematocrit time series exposed to the top-10 ATC-3
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(b) Time series non-exclusively exposed to one
of the top-10 ATC-4 concepts.
Figure A.20: Density heatmap of irregular hematocrit time series exposed to the top-10 ATC-4
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(b) Time series non-exclusively exposed to one
of the top-10 ATC-5 concepts.
Figure A.21: Density heatmap of irregular hematocrit time series exposed to the top-10 ATC-5
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(b) Time series non-exclusively exposed to one
of the top-10 RxNorm concepts.
Figure A.22: Density heatmap of irregular hematocrit time series exposed to the top-10 RxNorm
concepts ranked by KS statistics.
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A.2. REGULAR TIME SERIES: MODEL TUNING AND SELECTION
A.2 Regular time series: Model tuning and selection
A.2.1 Urea nitrogen (3094-0)
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A.2. REGULAR TIME SERIES: MODEL TUNING AND SELECTION
















MLP - regular time series - best model
Figure A.25: Best MLP model for urea nitrogen regular time series.
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A.2. REGULAR TIME SERIES: MODEL TUNING AND SELECTION
















LSTM - regular time series - best model
Figure A.28: Best LSTM model for urea nitrogen regular time series.
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A.2. REGULAR TIME SERIES: MODEL TUNING AND SELECTION
















CNN - regular time series - best model
Figure A.31: Best CNN model for urea nitrogen regular time series.
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A.2. REGULAR TIME SERIES: MODEL TUNING AND SELECTION
repeat - training error repeat - testing error
linReg - training error linReg - testing error
RFR - training error RFR - testing error
MLP - training error MLP - testing error
LSTM - training error LSTM - testing error
CNN - training error CNN - testing error
Figure A.32: Heatmap of averaged MSE for the dierent forecasting models on urea nitrogen
regular time series.
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A.2.2 Hematocrit (20570-8)
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MLP - regular time series - best model
Figure A.35: Best MLP model for hematocrit regular time series.
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A.2. REGULAR TIME SERIES: MODEL TUNING AND SELECTION















LSTM - regular time series - best model
Figure A.38: Best LSTM model for hematocrit regular time series.
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A.2. REGULAR TIME SERIES: MODEL TUNING AND SELECTION















CNN - regular time series - best model
Figure A.41: Best CNN model for hematocrit regular time series.
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A.2. REGULAR TIME SERIES: MODEL TUNING AND SELECTION
repeat - training error repeat - testing error
linReg - training error linReg - testing error
RFR - training error RFR - testing error
MLP - training error MLP - testing error
LSTM - training error LSTM - testing error
CNN - training error CNN - testing error
Figure A.42: Heatmap of averaged MSE for the dierent forecasting models on hematocrit reg-
ular time series.
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A.3. IRREGULAR TIME SERIES WITH TIME INTERVALS: MODEL TUNING AND SELECTION
A.3 Irregular time series with time intervals: Model tuning
and selection
A.3.1 Urea nitrogen (3094-0)
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A.3. IRREGULAR TIME SERIES WITH TIME INTERVALS: MODEL TUNING AND SELECTION
















MLP - irregular time series - best model
Figure A.45: Best MLP model for urea nitrogen irregular time series with time intervals.
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A.3. IRREGULAR TIME SERIES WITH TIME INTERVALS: MODEL TUNING AND SELECTION
















LSTM - irregular time series - best model
Figure A.48: Best MLP model for urea nitrogen irregular time series with time intervals.
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A.3. IRREGULAR TIME SERIES WITH TIME INTERVALS: MODEL TUNING AND SELECTION
















CNN - irregular time series - best model
Figure A.51: Best MLP model for urea nitrogen irregular time series with time intervals.
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A.3. IRREGULAR TIME SERIES WITH TIME INTERVALS: MODEL TUNING AND SELECTION
A.3.2 Hematocrit (20570-8)
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A.3. IRREGULAR TIME SERIES WITH TIME INTERVALS: MODEL TUNING AND SELECTION















MLP - irregular time series - best model
Figure A.54: Best MLP model for hematocrit irregular time series with time intervals.
239



















































































































































































































































































































































































































































































































































































A.3. IRREGULAR TIME SERIES WITH TIME INTERVALS: MODEL TUNING AND SELECTION















LSTM - irregular time series - best model
Figure A.57: Best MLP model for hematocrit irregular time series with time intervals.
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A.3. IRREGULAR TIME SERIES WITH TIME INTERVALS: MODEL TUNING AND SELECTION















CNN - irregular time series - best model
Figure A.60: Best CNN model for hematocrit irregular time series with time intervals.
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A.4. IRREGULAR TIME SERIES WITH AUXILIARY DRUG EXPOSURES: SUPPLEMENTARY
RESULTS
A.4 Irregular time serieswith auxiliary drug exposures: sup-
plementary results
A.4.1 Fine tuning and model selection
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A.4. IRREGULAR TIME SERIES WITH AUXILIARY DRUG EXPOSURES: SUPPLEMENTARY
RESULTS















MLP - irregular time series - best model
Figure A.63: Best MLP model for irregular glucose lab time series with auxiliary drug exposure
by ATC-3, 10 drugs, during tuning.
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A.4. IRREGULAR TIME SERIES WITH AUXILIARY DRUG EXPOSURES: SUPPLEMENTARY
RESULTS















MLP - irregular time series - best model
Figure A.66: Best MLP model for irregular glucose lab time series with auxiliary drug exposure
by ATC-4, 5 drugs, during tuning.
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A.4. IRREGULAR TIME SERIES WITH AUXILIARY DRUG EXPOSURES: SUPPLEMENTARY
RESULTS















MLP - irregular time series - best model
Figure A.69: Best MLP model for irregular glucose lab time series with auxiliary drug exposure
by ATC-4, 10 drugs, during tuning.
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A.4. IRREGULAR TIME SERIES WITH AUXILIARY DRUG EXPOSURES: SUPPLEMENTARY
RESULTS















MLP - irregular time series - best model
Figure A.72: Best MLP model for irregular glucose lab time series with auxiliary drug exposure
by ATC-5, 5 drugs, during tuning.
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A.4. IRREGULAR TIME SERIES WITH AUXILIARY DRUG EXPOSURES: SUPPLEMENTARY
RESULTS















MLP - irregular time series - best model
Figure A.75: Best MLP model for irregular glucose lab time series with auxiliary drug exposure
by ATC-5, 10 drugs, during tuning.
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A.4. IRREGULAR TIME SERIES WITH AUXILIARY DRUG EXPOSURES: SUPPLEMENTARY
RESULTS















MLP - irregular time series - best model
Figure A.78: Best MLP model for irregular glucose lab time series with auxiliary drug exposure
by RxNorm, 5 drugs, during tuning.
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A.4. IRREGULAR TIME SERIES WITH AUXILIARY DRUG EXPOSURES: SUPPLEMENTARY
RESULTS















MLP - irregular time series - best model
Figure A.81: Best MLP model for irregular glucose lab time series with auxiliary drug exposure
by RxNorm, 10 drugs, during tuning.
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A.4. IRREGULAR TIME SERIES WITH AUXILIARY DRUG EXPOSURES: SUPPLEMENTARY
RESULTS
repeat - training error repeat - testing error
linReg - training error linReg - testing error
RFR - training error RFR - testing error
MLP - training error MLP - testing error
(a) ATC-4 with 5 drugs.
repeat - training error repeat - testing error
linReg - training error linReg - testing error
RFR - training error RFR - testing error
MLP - training error MLP - testing error
(b) ATC-4 with 10 drugs
Figure A.82: Heatmap of MSE errors by model for glucose lab irregular time series with ATC-4
exposure representation with 5 and 10 drugs.
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A.4. IRREGULAR TIME SERIES WITH AUXILIARY DRUG EXPOSURES: SUPPLEMENTARY
RESULTS
repeat - training error repeat - testing error
linReg - training error linReg - testing error
RFR - training error RFR - testing error
MLP - training error MLP - testing error
(a) ATC-5 with 5 drugs
repeat - training error repeat - testing error
linReg - training error linReg - testing error
RFR - training error RFR - testing error
MLP - training error MLP - testing error
(b) ATC-5 with 10 drugs
Figure A.83: Heatmap of MSE errors by model for glucose lab irregular time series with ATC-5
exposure representation with 5 and 10 drugs.
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A.4. IRREGULAR TIME SERIES WITH AUXILIARY DRUG EXPOSURES: SUPPLEMENTARY
RESULTS
repeat - training error repeat - testing error
linReg - training error linReg - testing error
RFR - training error RFR - testing error
MLP - training error MLP - testing error
(a) RxNorm with 5 drugs
repeat - training error repeat - testing error
linReg - training error linReg - testing error
RFR - training error RFR - testing error
MLP - training error MLP - testing error
(b) RxNorm with 10 drugs
Figure A.84: Heatmap of MSE errors by model for glucose lab irregular time series with RxNorm
exposure representation with 5 and 10 drugs.
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Chapter B
conditional WGAN: additional drug
representation models
B.1 ATC-3 auxiliary information
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B.2. ATC-4 AUXILIARY INFORMATION
B.2 ATC-4 auxiliary information
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B.3. ATC-5 AUXILIARY INFORMATION
B.3 ATC-5 auxiliary information
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B.4. RXNORM AUXILIARY INFORMATION
B.4 RxNorm auxiliary information
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Proof of concept: NIPS ML4H workshop
2017
is paper was accepted at the Machine Learning for Health Workshop at NIPS (ex-NeurIPS) 2017
in Long Beach. While the GAN model was still relying on the ”Vanilla GAN” framework, with
a twist inspired by the medGAN paper[35], it was the proof of concept that we could generate
laboratory test time series, and that conditional information was positively aecting the mod-
els. Some of the ideals in this paper matured into this dissertation, while others help shape the
dierent experimental approach described throughout the dierent aims of this document.
C.1 Data
Our electronic health records (EHR) data were collected at the New York Presbyterian/Columbia
University Irving Medical Center between 2000 and 2013 with 19.6 million drug prescriptions
for 485,306 patients and 473.6 million laboratory test observations. We selected all the patients
exposed to HMG-CoA reductase inhibitors, or statins (ATC code C10AA) at any point in time. For




We identied 65,563 patients exposed to any statin in the inpatient seing, with a total of
411,880 total cholesterol measurements (average per patient: 8.4, min:1, max:313). Aer pre-
processing their total cholesterol measurement series, and excluding patients with no measure-
ment during drug exposure and patient without measurements within a year before exposure,
we ended up with 4,830 patients (50.6% females) with an average age at statin exposure of 65.15
(SD: 12.25). Each patient was associated with one interpolated time series of total cholesterol
of 16 points (8 measurements before, 8 measurements during exposure). No patient had enough
data to have more than one before/during exposure measurement series according to our criteria.
Our cohort presented an average total cholesterol value of 170.6 mg/dL (SD: 56.79) before statin
exposure, and 160.7 mg/dL (SD: 50.98) during statin exposure, signicantly lower (p < 10−79),
compared to the average of 185.3 mg/dL (SD: 50.48) for the 1,345,017 values available in our EHR
system. e 99 percentile interval of total cholesterol for this cohort was [75− 319] mg/dL.
C.2 Pre-processing
For each patient exposed to statins, we annotated the total cholesterol measurements to deter-
mine if they were falling inside or outside a window of continous exposure to a statin with no
gap larger than 30 days. We split these timelines on and o drug into segments of measurements
during an exposure era preceded by measurements o-exposure at most a year before the be-
ginning of the drug era. Exposure eras without pre-exposure data following these criteria were
excluded. In order to feed our neural networks vectors of xed length, we performed a linear
interpolation weighted by the measurement dates to have the same number of points before and
during drug exposure. In order not to distort the paern between before and during drug expo-
sure, we made sure to interpolate independently the pre-exposure measurements and the during
exposure measurements. Finally, for beer training performances with our GANs architecture,
we linearly normalized between -1 and 1 all these time series using the 99th percentile values
272
C.3. DEEP PATIENTS STRATIFICATION
of total cholesterol measurements at any point in time for patients exposed to statins, which
removed potentially erroneous values and extreme outliers. Values exceeding this range were
brought back to -1 if too low and 1 if too high.
C.3 Deep patients stratication
We collected clinical covariates for our cohort in the period before drug exposure: drug prescrip-
tions in the form of ATC codes and ICD-9 diagnoses code that we grouped by 3-digit codes. We
trained a deep autoencoder with four encoding layers (256, 128, 64, 32) and four decoding layers
on these binary features before exposure. is approach is analogous to the Deep Patient model
[124]. We then applied the t-SNE algorithm developed by Maaten and Hinton [114] to represent
patients in two dimensions and clustered with spectral clustering.
By compressing the 1524 clinical features into 32 dimensions with our deep autoencoder and
representing them in two dimensions using t-SNE, we identied two clearly dened clusters and
one larger cluster that the spectral clustering cut in two. Remarkably, cluster 3 was solely com-
posed of type 2 diabetes patients. We trained GANs on the total cohort (totalGAN) and on each
cluster (subGANs) and represented the average synthetic time series they generated compared to
the real one with their standard deviation (Figure C.1). We then evaluated the accuracy of sub-
GANs against the totalGAN using the similarity and prediction MSE described in the Methods
section above.
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Figure C.1: A. Clustered t-SNE representation of the time series encoded using clinical co-
variates B. Comparison of the average time series generated by the GANs trained on each cluster
with the real time series.
C.4 Generative Adversarial Network training
We used the mini-batch averaging method proposed by [35] with some notable dierences: the
model was performing best when the autoencoder’s encoder layer had the same size as the input,
therefore not compressing but simply identifying meaningful features. We selected atanh recon-
struction function and evaluated the loss with a mean square error given the continuous nature
of our normalized time series. e generator had a single layer of size 16, and the discriminator
had two layers of sizes 32 and 16. Given the low number of features that we had, we avoided
over-ing the model by having too many hidden units. Each GAN was trained on 100 epochs
and with a batch size of 10, except for the smallest cluster that was trained with a batch size of 5.
C.5 Evaluation of GAN outputs
Our evaluation process was 2-tiered: rst, we evaluated the presence and magnitude of the drug
eect using a paired t-test on the average values before and during drug exposure for each mea-
surement segment. We dened the eect size as the mean of the dierences between both groups
of measurements. Second, we evaluated how predictive synthetic time series were as a measure
of delity to the real data. To do so, we used the mean square error MSEpre(x, xˆ) as a measure
of similarity between a real time series x and a synthetic one xˆ using the before exposure values
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only. e predictivity error was expressed as the mean square error MSEexp(x, xˆ) on the values
during exposure only. To evaluate the predictivity of a set SˆV of V synthetic series for a given
set SN of N real series, we expressed the predictivity error Perr as:








which is the mean of the predictivity errors from each real series xk with its most similar syn-
thetic series based on the pre-exposure measurements. For each cluster identied, we compared
Perr between the GAN trained on the whole cohort, and the GAN trained on the cluster of inter-
est. For each GAN model we generate 10 times more synthetic samples than the largest cluster,
and then sampled as many synthetic time series as there are real ones. e random clusters were
obtained with sampling without replacement and were the same size as the real clusters for each
test.
Table C.1: Predictivity error Perr (± SD)
Clinical Clusters Random Clusters
Cluster subGAN totalGAN p-value subGAN totalGAN p-value
Cluster 0 0.13 (±0.22) 0.16 (±0.28) 5.7e-4 0.27 (±0.39) 0.16 (±0.27) 2.0e-303
Cluster 1 0.15 (±0.27) 0.16 (±0.26) 1.5e-1 0.30 (±0.45) 0.16 (±0.26) 2.2e-308
Cluster 2 0.11 (±0.21) 0.22 (±0.35) 3.9e-5 0.24 (±0.40) 0.15 (±0.26) 1.1e-21
Cluster 3 0.12 (±0.20) 0.15 (±0.24) 3.9e-4 0.28 (±0.38) 0.16 (±0.27) 1.5e-144
e real data of each cluster was signicantly beer predicted by the subGANs than by the
totalGAN for all clusters except for Cluster 1. Moreover, subGANs trained on random clusters of
identical size signicantly performed worse than the clinically relevant ones (Table 1), hinting at




In this study, we presented an unsupervised framework to evaluate generative adversarial net-
works for the prediction of drug-induced laboratory test trajectories. is framework is applica-
ble to any time series aected by a known exposure factor. We dened a similarity measure to
align synthetic time series to real ones before exposure and a metric to evaluate the prediction
performances of synthetic time series during the exposure period. Further, we demonstrated that
clinical variables can be integrated to identify meaningful clusters that produce signicantly more
accurate GANs with regard to exposure trajectory prediction. By using a deep autoencoder, we
hint at the potential for integrating neural network-based compressed representations of patients
into conditional GANs architectures while keeping evaluations completely unsupervised. Such
architectures would also direct the synthetic data generation to ensure an increased similarity
with the real data.
C.7 Total cholesterol distributions
In this section, we provide the total cholesterol distributions’ statistics and gures for the dierent
cohorts mentions in the Results section. Normal ranges for total cholesterol (LOINC 2093-3) are
below 200 mg/dL. Between 200 and 240 mg/dL the level is considered to be borderline high. Total
cholesterol is considered to be high for values above 240 mg/dL. As mentioned in the Results
section, we collected a total of 411,880 total cholesterol measurements in the period of interest
of our retrospective study. e minimal value measured was 0.0 and the maximal value was
3368 mg/dL, yielding an average of 184.6 mg/dL (± 45.58). To remove outliers in that study, we
only considered the 99 percentiles as represented in Figure C.2 showing the density estimate
distribution of total cholesterol values over all patients between 2000 and 2013.
Figure C.3 represents the laboratory test measurements aer linear interpolation and linear
normalization using the 99 percentile extremal values as normalization bounds, for the complete
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Figure C.2: 99 percentiles of the total cholesterol distribution for all patients in our clinical data
warehouse between 2000 and 2013, with total cholesterol (LOINC 2093-3) normal ranges.
cohort for all time points, for the measurements before exposure, and the measurement during
exposures, and the four sub clusters identied using clinical variables as described in the Methods
section 2.3.
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Normalized total cholesterol measurements distributions






Figure C.3: Normalized total cholesterol measurements for the complete statin cohort, and the
4 sub-clusters, overall (TOTAL), before exposure, and during exposure to statins.
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C.8 Generated time series gures
In this subsection, we present randomly selected real time series from each of the four sub clusters
with the synthetic time series from the GAN trained on the whole cohort (totalGAN), and the
GAN trained on the specic cluster (subGAN) that were the closest before exposure to provide




Figure C.4: Cluster 0.
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Figure C.5: Cluster 1.
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Figure C.6: Cluster 2.
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Figure C.7: Cluster 3.
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